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7ABSTRACT
The aims of this study were to investigate chromosomal and genetic changes in gastric cancer, 
particularly in its intestinal type, and Barrett adenocarcinoma, and to characterize frequently 
ampliﬁ ed and overexpressed genes in the long arm of chromosome 17.     
In this thesis, DNA copy number changes were investigated in 18 Barrett adenocarcinoma and 
22 gastric cancer patients aged ≤ 45, and in three cell lines established from patients aged ≤ 45, 
using comparative genomic hybridization (CGH). One of the most common changes in Barrett 
adenocarcinoma was gain at 17q. Other frequent gains were detected in 7 and 20q. The most 
common losses were seen in chromosomes 4 and 5. These results suggest similarities in DNA copy 
number changes that CGH had previously revealed in the intestinal type of gastric cancer. CGH 
results of younger gastric cancer patients showed overall similarity with older patients, including 
the frequently ampliﬁ ed region of 17q. We observed, however, ampliﬁ cation in chromosome 
19 at a signiﬁ cantly higher frequency in younger patients (68%) than in older patients (up to 
30%) previously studied by CGH. The 19q region harbors several candidate oncogenes. We 
selected CCNE, CEBPA, AKT2, TGFB, and BCL3 for further investigation. We identiﬁ ed one 
ampliﬁ ed and upregulated gene, cyclin E, by in situ hybridization (ISH), Southern blot, and 
immunohistochemistry (IHC). 
Gain at 17q is frequent in the intestinal type of gastric cancer. In order to investigate the 
comprehensive ampliﬁ cation and expression proﬁ le of target genes in gastric cancer and Barrett 
adenocarcinoma, we employed with a custom-made chromosome 17-speciﬁ c cDNA-microarray. 
A total of 636 genes and ESTs were analyzed in the cDNA array to determine the copy number 
and expression levels of eight xenografts and three cell lines. Ampliﬁ cation and expression 
analysis of xenografts and cell lines revealed only three genes that were frequently ampliﬁ ed and 
overexpressed, DARPP32, TOP2A, and ERBB2. These results were validated with Northern blot 
and RT-PCR. The GAS gene, also located at 17q, was not included in the cDNA-microarray chip 
and was studied separately in ten primary tumors and one cell line by ISH. GAS gene ampliﬁ cation 
was detected in the intestinal tumors with the 17q amplicon. GAS protein expression was veriﬁ ed 
in the gastric cancer cell line by Western blot.
To examine the ampliﬁ cation and expression status of DARPP32, TOP2A, and ERBB2 
in primary gastric cancer tumors, we performed ISH and IHC on a tumor tissue array and 
quantitative real-time PCR on primary tumor samples. The ISH analysis of 52 gastric carcinomas 
revealed concomitant ampliﬁ cation of DARPP32, TOP2A and ERBB2 in 17% of the intestinal type 
cases. Interestingly, DARPP32, TOP2A, and ERBB2 were not concomitantly expressed. Of the 29 
cases we analyzed by real-time PCR, ERBB2 was overexpressed in one case (3%) and TOP2A in 
ﬁ ve cases (17%), whereas DARPP32 was overexpressed in fourteen (48%) cases. We performed 
IHC to conﬁ rm that the RNA expression of DARPP32 and ERBB2 correlated with the protein level. 
The frequency of samples showing protein overexpression was in agreement with results from the 
real-time PCR study: 45% for DARPP32 (30/66) and 4.5% for ERBB2 (3/66).
This study has provided information concerning aberrations in several chromosomal regions 
in gastric cancer and Barrett adenocarcinoma, and narrowed down critical candidate genes that 
can be the focus of further studies.
8INTRODUCTION
Gastric cancer is one of the most common malignancies worldwide. Data provided by the 
International Agency for Research on Cancer (Ferlay et al., 2001) revealed that gastric cancer was 
the second most common cancer in males in the year 2000. In 2000, the age-adjusted incidence of 
gastric cancer in developed countries was 24.6/100 000 in males and 11.0/100 000 in females. In 
Finland, the annual number of new gastric cancer cases was 386 for males and 336 for females in 
2001 (Finnish Cancer Registry). Incidence rates of gastric cancer are highest in Japan, Korea, China, 
Eastern Europe, and in several regions of South America (Ferlay et al., 2001). In recent decades, 
the incidence of proximal gastric cancer, i.e., adenocarcinoma of the cardia and gastro-esophageal 
junction, and Barrett adenocarcinoma, has increased in the Western world [(Devesa et al., 1998; 
Brown et al., 2002; Kelley et al., 2003) and references therein] for reasons that are unclear. 
Gastric cancer is classiﬁ ed histologically into two subtypes: intestinal and diffuse. The 
intestinal-type gastric cancer is more common in older age-groups, and geographically in high-
incidence areas [(Kelley et al., 2003) and references therein]. 
Bacterial infection with Helicobacter pylori is a major risk factor for gastritis leading to 
carcinoma in the distal stomach. The World Health Organization (WHO) classiﬁ es H. pylori as a 
potential carcinogen. Diet is another strong environmental risk factor for gastric cancer [reviewed 
by Fenoglio-Preiser et al. in (Hamilton et al. (ed), 2000)].
Most gastric cancers are sporadic. Comparative genomic hybridization (CGH) and loss of 
heterozygosity studies have revealed recurrent target chromosomal regions for gene ampliﬁ cations 
and losses in gastric cancer. Several gene alterations have been associated with gastric cancer and 
its speciﬁ c subtype, but our knowledge of gastric cancer tumorigenesis is still limited.
Knowledge of cancer genetics will provide tools for the characterization of different histological 
subtypes, discovery of new prognostic tumor markers, and development of more speciﬁ c cancer 
treatments. The present study was undertaken to characterize frequent genetic aberrations in 
gastric cancer, particularly in the intestinal subtype, and Barrett adenocarcinoma.
Figure 1. Diagram of the stomach
9REVIEW OF THE LITERATURE
1. ADENOCARCINOMA OF THE STOMACH 
The incidence of adenocarcinoma of the stomach, with the exception of adenocarcinoma of 
the cardia (see Chapter 2), has decreased in the Western world over the past several decades. 
Reasons for this are better living conditions and improvements in diet. Still, gastric cancer is one 
of the leading causes of cancer-related death worldwide. In the western world most diagnosed 
gastric cancers are advanced tumors with poor prognosis. More than 90% of the stomach tumors 
are adenocarcinomas. [See reviews (Fenoglio-Preiser et al. in (Hamilton et al. (ed.), 2000)), 
Hohenberger et al., 2003]. 
Several histological classiﬁ cations have been developed. The Laurén and WHO classiﬁ cations 
are the most commonly used. The Laurén classiﬁ cation divides tumors into two major types based 
on their histology: intestinal and diffuse (Lauren, 1965). Intestinal carcinoma is characterized by 
tubular glandlike structures and cohesion between the tumor cells (Lauren, 1965). The diffuse 
type inﬁ ltrates the gastric wall, tumor cells lack cohesion or are poorly cohesive, and the cells are 
usually round and small, and occur as single cells or form clusters (Laurén, 1965), [reviewed by 
Fenoglio-Preiser et al. in (Hamilton et al. (ed.), 2000)].
The four major types of carcinoma in the WHO classiﬁ cation are tubular adenocarcinoma, 
papillary adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma. A few rare 
stomach carcinomas, e.g., adenosquamous and squamous cell carcinomas, match neither of the 
above classiﬁ cations. [Reviewed by Fenoglio-Preiser et al. in (Hamilton et al. (ed.), 2000)]. 
     
2. ADENOCARCINOMA OF THE GASTRO-ESOPHAGEAL JUNCTION
Carcinomas typically included in the category of adenocarcinoma of the gastro-esophageal 
junction are adenocarcinomas of the Barrett esophagus and the cardia [reviewed by Spechler et 
al. in (Hamilton et al. (ed.), 2000)]. Barrett esophagus is deﬁ ned as an intestinal metaplasia of the 
distal esophagus where the normal squamous epithelium is replaced by metaplastic columnar 
epithelium containing goblet cells (Haggitt, 1994). Barrett esophagus has been estimated to cause 
a 30 to 125-fold increased risk for adenocarcinoma (Haggitt, 1994 and references therein).
The incidence of carcinomas arising within the gastro-esophageal junction has increased 
over previous decades as compared with carcinomas arising in the distal stomach [(Falk, 2002; 
Velanovich et al., 2002; Wang et al., 2003; Wild et al., 2003) and references therein]. Reasons for this 
development are unknown. Gastro-esophageal reﬂ ux disease is a known precursor for Barrett 
esophagus, however.     
Similarities in epidemiology, pathology, and clinical characteristics suggest that 
adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia are one and 
the same disease (Kalish et al., 1984; Haggitt, 1994; Ruol et al., 2000; Weiss et al., 2003). H. pylori 
infection has not been reported as a precursor of Barrett esophagus [reviewed in (Buttar et al., 
2001)].
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3. PATHOGENESIS AND RISK FACTORS FOR CARCINOMAS IN THE STOMACH AND 
GASTRO-ESOPHAGEAL JUNCTION
3.1 Pathogenesis of gastric carcinoma
The carcinogenic pathway in intestinal-type gastric cancer develops through well-known 
sequential stages, whereas the mechanism behind development of diffuse-type gastric cancer 
is not well known. The sequential stages leading from normal gastric mucosa to intestinal-type 
gastric cancer start from acute, chronic, and atrophic gastritis through to intestinal metaplasia and 
dysplasia, and end with adenocarcinoma [reviewed by Spechler et al. in (Hamilton (ed.) 2000)], 
(Yuasa, 2003). Figure 2 shows the pathogenetic route of gastric adenocarcinoma. Precursory 
changes in diffuse-type gastric cancer are not known. The majority of gastric cancers are sporadic, 
only around 10% of cases are familial (Caldas et al., 1999). A germline mutation of the E-cadherin 
(CDH1) gene is associated with hereditary diffuse-type gastric cancer (Gayther et al., 1998; 
Guilford et al., 1998). 
Figure 2. Pathogenetic pathway of gastric adenocarcinoma [modiﬁ ed from Spechler et al. in (Hamilton 
(ed.) 2000)]. 
3.2 Risk factors in gastric cancer
Infection with H. pylori, speciﬁ cally the CagA+ strain, is a major factor increasing gastric cancer 
risk (Sipponen et al., 1992; Blaser, 1998), [reviewed in (Ernst et al., 2000; Yuasa, 2003)]. CagA is 
a cytotoxic bacterial protein transferred into the host cell during H. pylori infection (Ernst et 
al., 2000). H. pylori binds to the gastric epithelial cells, damaging and causing disorder in the 
epithelium, leading to gastric inﬂ ammation and acute gastritis (Ernst et al., 2000). In addition, 
bacterial infection is associated with development of gastroduodenal ulcers (Ernst et al., 2000). A 
recent study in a transgenic mouse model conﬁ rmed that H. pylori infection induces mutations 
in gastric mucosa (Touati et al., 2003). The molecular mechanism of bacterial infection leading to 
gastric cancer has yet to be established. 
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Increased risk of gastric cancer has been associated with smoked and cured food and food 
with a high concentration of salt [reviewed by Fenoglio-Preiser et al. in (Hamilton (ed) 2000) and 
reviewed in (Yamaguchi et al., 2001)]. N-nitroso compounds are carcinogens, and found in cured 
and smoked food. Most N-nitroso compounds are synthesized in the stomach through nitrozation 
by nitrites of amines or amides. Low acidity, acidity of gastric juice, and catalyzation of bacteria 
are factors associated with nitrozation in the stomach. (Yamaguchi et al., 2001). Fresh fruits and 
vegetables are protective against gastric cancer due to their antioxidant effect. Peptic ulcer disease, 
gastrectomy performed for gastric ulcer, and pernicious anemia are also recognized risk factors 
for gastric cancer. The signiﬁ cance of alcohol and smoking in the development of gastric cancer is 
unclear. [Reviewed in (Kelley et al., 2003)]. 
3.3 Pathogenesis and risk factors in Barrett esophagus
Barrett esophagus develops when normal esophageal squamous epithelium is replaced by 
columnar epithelium, typically as a result of chronic gastro-esophageal reﬂ ux disease [reviewed 
by Werner et al. in (Hamilton et al. (ed.), 2000)]. Barrett esophagus is the most important precursor 
and risk factor for development of adenocarcinoma of the lower esophagus or gastro-esophageal 
junction [reviewed by Werner et al. in (Hamilton et al. (ed.), 2000)]. Dysplasia arises from the 
metaplastic epithelium and leads progressively to adenocarcinoma of Barrett esophagus. Figure 
3 shows the pathogenetic pathway of Barrett adenocarcinoma. H. pylori infection has not been 
found as a precursor or risk factor for gastro-esophageal reﬂ ux disease, Barrett esophagus, or 
adenocarcinoma of the esophagus and gastric cardia, but it is considered a major risk factor for 
cancer in the distal stomach [reviewed in (Blaser, 1998)], (Chow et al., 1998). Other risk factors 
promoting the development of gastro-esophageal reﬂ ux or Barrett esophagus are obesity, dietary 
fat, and smoking. In addition, alcohol, medication, and genetic factors are also suggested to be 
associated with increased risk. [Reviewed in (Wild et al., 2003)].
Figure 3. Pathogenetic pathway of Barrett adenocarcinoma. 
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4. CYTOGENETIC AND MOLECULAR GENETIC ABERRATIONS IN GASTRIC CARCINOMA
4.1 DNA copy number changes in gastric carcinoma
Gene ampliﬁ cation is an important mechanism for oncogene function. The comparative genomic 
hybridization (CGH) method makes it possible to screen chromosomal alterations; gain and 
losses of DNA sequences. Recurrent copy number ampliﬁ cations and oncogenes involved in 
ampliﬁ cations have been observed in various human cancers [see review (Knuutila et al., 1998)]. 
Demands associated with the CGH technique are good quality of metaphase preparations, 
optimized hybridization conditions, and quantitative image analysis (Forozan et al., 1997; 
Karhu et al., 1997). Samples for CGH should contain more than 50% tumor cells for quantitative 
observation of chromosomal changes. In addition, CGH requires well-characterized specimens. 
Table 1 summarizes the most frequent chromosomal aberrations revealed by ﬁ ve CGH 
studies. In gastric carcinoma the most frequent gains were seen at chromosomes 1, 7, 8q, 12, 17q, 
and 20q, and losses at 4q, 5q, and 18. In intestinal-type cancer the most frequent ampliﬁ cations 
were found at 8, 17q, and 20q. High-level ampliﬁ cations were frequent at 17q, and 20q. Frequent 
aberrations in chromosomes 4, 5, 8, 17, and 20 were observed in each study. Ampliﬁ cation at 17q 
was more frequent in intestinal-type than in diffuse-type gastric cancer. The frequencies of DNA 
copy number gains in chromosome 8 ranged from 33% to 59%, at 17q from 18% to 45%, and at 
20q from 23% to 59%. The highest frequencies were observed in xenografted tumors (El-Rifai et 
al., 2001), probably due to high purity of tumor cells in xenografted specimens. The frequencies 
of losses at 4q varied from 15% to 53% and at 5 from 12% to 53%. Ampliﬁ cation at 17q was also 
found in a severe dysplastic tumor (Kokkola et al., 1998). 
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Table 1. Most frequent DNA copy number changes, summarized from ﬁ ve studies of 
gastric carcinoma and Barrett adenocarcinoma 
Study Gains (frequency %) Losses (frequency %) No. of samples/ 
classiﬁ cation
Kokkola et al., 
(1998)
Kokkola et al., 
(1997)
1 high-level ampliﬁ cation of 17q 
in severe dysplasia
1q (20%), 8q (37%), 17q12-21 
(29%), 20q (46%)
Intestinal
8q (37%), 17q12-q21 (41%), 
20q (55%)
High-level ampliﬁ cations 
(intestinal)
17q12-q21, 20q, 2p
4q (23%), 18q (26%)
Intestinal
4q (32%), 18q (41%)
16 dysplasia (13 moderate, 
3 severe)
35 primary gastric 
carcinomas including
22 intestinal, 13 diffuse  
El-Rifai et al., 
(2001)
5p (38%), 6p (29%), 7q (38%), 
8q (56%), 12p (29%), 12q (29%), 
17q (59%), 20q (74%)
Gastric carcinoma
8q (59%), 17q (45%), 20q 59%)
High-level ampliﬁ cations
2q, 3q, 4p, 6, 7, 8, 9p, 10p, 11q, 
12, 13, 14q, 15, 17q, 20q, 22
4q (53%), 5q (53%) 9p 
(47%)
Gastric carcinoma
4 (50%), 5 (45%)
34 xenografted 
adenocarcinomas
arising from Barrett 
esophagus (12 cases) 
and gastric mucosa (12 
intestinal, 6 diffuse, 2 mixed 
and 2 atypical)
Wu et  al., 
(2001)
6q (26%), 7p (23%), 8q (43%), 
11q (26%), 13q (24%), 17q (23%), 
20q (23%)
High-level ampliﬁ cations
3p, 4q, 6q, 11q, 12p, 13q, 17q, 20q
Intestinal
8q (64%), 17q (39%)
1p (15%), 3p (15%), 4q 
(15%), 5q (19%), 16q 
(26%), 19p (23%)
Intestinal
3p (25%), 5q (32%)
53 primary gastric 
carcinomas including
28 intestinal type
25 diffuse type
Tay et  al., 
(2003)
1 (20%), 7 (33%), 8 (33%), 
12 (22%), 13(25%), 
17 (18%), 20 (47%)
High-level ampliﬁ cations
2q, 3, 5p, 6p, 7p, 8q, 9p, 10p, 11p, 
12, 13, 14, 16, 17q, 18, 19q, 20q
Intestinal
7 (39%), 8 (39%), 17q (24%), 
20q (49%)
4 (20%), 5 (12%)
18 (15%)
Intestinal
4 (22%), 5q (17%), 18 
(20%)
60 primary gastric 
carcinomas including
41 intestinal,
17 diffuse and
2 mixed
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4.2 Chromosome 17q gain in human malignancies
In addition to its important role in gastric cancer, gains at 17q are frequent in other human 
malignancies. Breast cancer is the most studied malignancy associated with the 17q amplicon. 
In breast cancer the target region in chromosome 17 has been characterized to 17q12-q21 and 
17q23 bands (Kauraniemi et al., 2001; Monni et al., 2001). The 17q12-q21 region harbors the v-
ERBB2 avian erythroblastic leukaemia viral oncogene homolog 2 (ERBB2) and topoisomerase 2 
 (TOP2A) genes, and have been widely studied in breast cancer (Jarvinen et al., 1996; Jarvinen 
et al., 1999; Depowski et al., 2000; Tanner et al., 2001; Zhang et al., 2003). Both genes are targets for 
gene-speciﬁ c cancer therapy (Houlbrook et al., 1995; Baselga, 2001; Harris et al., 2001; Di Leo et 
al., 2002). Ampliﬁ cations at 17q have also been found at high frequency in neuroblastoma and 
implicated with poorer prognosis (Plantaz et al., 1997; Bown et al., 2001; Lastowska et al., 2002). 
A CGH study of classical Hodgkin lymphoma revealed frequent ampliﬁ cations in the 17q region 
(Chui et al., 2003).
   
4.3 Oncogenes involved in gastric carcinoma
4.3.1 Tyrosine kinases
A subclass of kinases, receptor tyrosine kinases (RTK), are responsible for the initiation of cellular 
signalling activation in processes such as cell proliferation, migration, and survival [see review 
(Ullrich, 2002)]. Some RTKs are frequently upregulated in cancer and are promising targets 
for gene-speciﬁ c anticancer therapy. The ERBB tyrosine kinase receptor family includes four 
genes: epidermal growth factor receptor (EGFR, ERBB1) (7p12), ERBB2 (HER2/Neu) (17q12-
21.1), ERBB3 (HER3) (12q13) and ERBB4 (HER4) (2q33-34).  In particular, EGFR and ERBB2 are 
frequently associated with human cancers. Gene-speciﬁ c agents are available for anticancer 
treatment against overexpression of EGFR (e.g. Geﬁ nitib) and ERBB2 (Trastuzumab). EGFR and 
its ligands (e.g., TGFA and EGF) are involved in epithelial proliferation and differentiation in skin, 
lung, pancreas, and the gastrointestinal tract [see review (Yarden et al., 2001)]. No speciﬁ c ligand 
has yet been found for the ERBB2 receptor. ERBB2 is suggested to function as a co-receptor with 
other ERBB-receptors [see review (Olayioye et al., 2000)]. Table 2 shows some important ligands, 
potential effector proteins, and signalling pathways in ERBB2 and EGFR signalling [see reviews 
(Alroy et al., 1997; Yarden et al., 2001; Burgess et al., 2003)]. The entire network of ERBB signaling 
is complicated and all ligands, pathways, and the ultimate outcome are not known. ERBB 
receptors form dimeric combinations. Ligand binding activates phosphorylation of the tyrosine 
phosphorylation site of the receptor to create a binding site for the effector protein.
Table 2. Components involved in the ERBB-signalling network
Ligands Effector proteins Signalling pathways
EGF, TGFA, -cellulin,
amphiregulin, epigen, 
epiregulin, HB-EGF
Src, Ras-GAP, PLC , Shc, Grb2, 
Grb7, Nck, Crk, Cbl 
Ras and Shc- activated MAPK-pathway,  
Akt pathway  (transcription factors e.g. Fos, 
Jun, Myc, Elk)
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In gastric cancer, the frequency of EGFR ampliﬁ cation is estimated to range from 3% to 5% and 
ERBB2 ampliﬁ cation from 10% to 20% [(Lin et al., 2000a) and references therein], (Park et al., 1989; 
Ishikawa et al., 1997; Ooi et al., 1998). Reports of ERBB2 protein overexpression in gastric cancer 
are few. Immunohistochemical studies with a wide series of samples have shown the frequency 
of ERBB2 protein upregulation to vary between 8% and 10% in gastric cancer (Ooi et al., 1998; 
Takehana et al., 2002). In breast cancer Herceptin therapy has been successful in patients with 
ERBB2 ampliﬁ cation/overexpression [see reviews (Leyland-Jones et al., 2001; Pegram et al., 2000)], 
(Baselga, 2001). Contemporaneous blocking of two or more ERBB receptors has been suggested to 
improve the efﬁ ciency of cancer therapy (Motoyama et al., 2002).
In addition to the ERBB family, gene ampliﬁ cations of some other tyrosine kinases, such as K-
SAM , C-MET, TIE-1, and AXL, are associated with gastric cancer (Hattori et al., 1990; Hara et al., 
1998; Lin et al., 1999; Lin et al., 2000a). K-SAM (10q26) is a receptor tyrosine kinase for ﬁ broblast 
growth factor (FGF) or keratinocyte growth factor (KFG). C-MET (7q31) codes  for a receptor 
tyrosine kinase for hepatocyte growth factor (HGF). TIE-1 (1p34-33) and AXL (19q13) are receptor 
tyrosine kinases. 
4.3.2 Other oncogenes
In addition to RTKs, several other oncogenes have been associated with gastric cancer. Avian 
myelocytomatosis viral (v-myc) oncogene homolog (c-MYC, mapped to 8q24) is an oncogene that 
encodes a transcription factor and is frequently overexpressed in human cancers. c-MYC normally 
functions in control of cell growth and proliferation and also in activation of apoptosis [see review 
(Pelengaris et al., 2003)]. c-MYC stimulates uncontrolled cell growth in cancer cells. Ampliﬁ cation 
of c-MYC has been reported in gastric cancer (Hara et al., 1998; Han et al., 1999). 
Topoisomerases, e.g. TOP2A, function in DNA replication, chromosome condensation and 
segregation [see review (Li et al., 2001)]. TOP2A is able to cleave double stranded DNA [see 
review (Berger, 1998)]. TOP2A (17q21) is known to be an ampliﬁ ed and overexpressed oncogene 
in breast cancer (Jarvinen et al., 1996, 1999; Depowski et al., 2000; Di Leo et al., 2002). Only a few 
genetic studies have been published about TOP2A in gastric cancer. Immunohistochemical studies 
have indicated TOP2A protein expression is higher in tumors than in normal gastric epithelium 
(Yabuki et al., 1996; Kim et al., 1999).  In breast cancer TOP2A is frequently found ampliﬁ ed or 
deleted in tumors with ERBB2 ampliﬁ cation (Jarvinen et al., 1999). TOP2A has also been identiﬁ ed 
as a potential target for anticancer drugs [see review (Topcu, 2001)].
Retrovirus associated sequence oncogene (K-RAS, 12p12) mutations are frequently observed in 
human cancers. K-RAS is a membrane protein and involved in the Ras/Raf/MEK/ERK pathway 
that controls cell growth, i.e., cell proliferation, transformation, differentiation, and apoptosis [see 
reviews (Kolch, 2000, 2003)]. Studies of K-RAS in gastric cancer have shown that the mutation 
frequencies vary from less than 5% up to 28% [(Arber et al., 2000; Yoo et al., 2002; Brennetot et al., 
2003) and references therein]. 
Caudal-type homeobox transcription factor 2 (CDX2, 13q12) is involved in normal intestinal 
development and differentiation (Silberg et al., 2000). In gastric cancer, abnormal expression 
of CDX2 at an early stage of carcinogenesis is suggested to induce development of intestinal 
metaplasia [see review (Yuasa, 2003)] (Bai et al., 2003). A transgenic mouse model supports this 
hypothesis (Silberg et al., 2002).
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Cyclooxygenase 2 (COX2, 1q25) is a rate-limiting enzyme catalyzing the biosynthesis of 
prostaglandins from arachidonic acid [see review (Vane et al., 1998)]. COX2 is a target for 
nonsteroid anti-inﬂ ammatory drugs (NSAIDs), such as aspirin, which inhibit the biosynthetie 
activity of the enzyme [see review (Vane et al., 1998)]. Elevated expression of COX2 has been 
observed in intestinal-type adenocarcinoma, at a frequency of approximately 60% of the samples 
(Ristimaki et al., 1997; Saukkonen et al., 2001), and also in dysplastic epithelium, suggesting COX2 
upregulation is an early event in tumorigenesis [see review (van Rees et al., 2001)]. Expression of 
COX2 has also been detected in stromal cells associated with erosion or ulceration (Saukkonen et 
al., 2001).  
The most frequent alterations observed in oncogenes are summarized in Table 3.
Table 3. Frequent oncogene alterations in gastric carcinoma
Gene Chromosomal 
location
Frequently found 
chromosomal gain 
by CGH
Gene 
ampliﬁ cation 
mRNA/protein
overexpression
Somatic 
mutation
ERBB2 17q12-q21.1 yes 10-20% 8-10%
EGFR 7p12 yes 3-5% ?
c-MYC 8q24 yes 15% 47%
TOP2A 17q21 yes ? 28% (I), 32% (D)
K-RAS 12p12 yes ? 5-28%
CDX2 13q12 yes ? 55% (85% IM)
COX2 1q25 yes ? 58% (I)
I, intestinal-type gastric cancer; D, diffuse-type gastric cancer; IM, intestinal metaplasia
4.4 Tumor suppressor genes involved in gastric carcinoma
Loss of gene function or of a gene involved in cell cycle regulation by deletion, mutation, or 
hypermethylation contributes to tumorigenesis.
One of the most studied tumor suppressor genes in gastric cancer is p53, mapped to 
chromosome 17p13. The p53 protein is a transcription factor which functions as a cell cycle 
regulator in G1/S and G2/M phase transitions [see review (Levine, 1997)]. p53 also has a role in 
the initiation of apoptosis [see review (Levine, 1997)]. The p53 protein is a major transcriptional 
regulator of cyclin-dependent kinase inhibitor (CDKI) p21, which is necessary to block the cell 
cycle in the G1 or G2 phase [(Bunz et al., 1998) and references therein]. Alteration in p53 is found 
in more than 50% of human cancers [see review (Levine, 1997)]. Allelic loss or mutations in p53 
have also been reported in gastric cancer (Gleeson et al., 1998; Okuyama et al., 2002; Fricke et al., 
2003; Lee et al., 2003), [see review (Fenoglio-Preiser et al., 2003)].
Loss of phosphatase and tensin homolog deleted on chromosome 10 (PTEN, mapped to 
10q23) gene expression has been detected in gastric cancer at a frequency of 20%. (Kang et al., 
2002). PTEN arrests the cell cycle at the G1 phase by negative regulation of the PI 3-kinase/Akt-
signalling pathway (Li et al., 1998). 
Chromosomal loss at 5q is a recurrent CGH ﬁ nding in gastric cancer studies. Adenomatous 
polyposis coli (APC) tumor suppressor gene is located at 5q21. Allelic loss of the APC locus has 
been implicated in gastric cancer (Powell et al., 1994, 1996; Lee et al., 2002b). However, although 
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mutations in APC and/or B-catenin are a known mechanism for accumulation of B-catenin and 
activation of the Wnt signalling pathway in colon cancer, these mutations are rare in gastric cancer 
(Lee et al., 2002b). The Wnt/B-catenin signal transduction pathway is associated with embryonic 
development in normal cells [see review (Henderson et al., 2002)]. 
The chromosomal region or part of the region of 18q is frequently found deleted in gastric cancer. 
Loss of heterozygosity (LOH) at the DCC (deleted in colorectal carcinoma) gene or 18q21 locus has 
been identiﬁ ed in gastric cancer (Uchino et al., 1992; Fang et al., 1998; Candusso et al., 2002). 
E-cadherin (CDH1, 16q22) is a Ca2+ dependent cell-to-cell adhesion molecule essential for 
function and formation of epithelial tissues [see reviews (Cano et al., 2000; Gumbiner, 2000)], 
(Braga, 2002). E-cadherin forms a multiprotein complex with catenins (A- and B-catenin). These 
complexes interact with the actin cytoskeleton [see review (Gumbiner, 2000)]. B-catenin can also 
function in the Wnt signalling pathway [(Berx et al., 1998) and references inthere]. Mutations in 
the CDH1 gene have even been observed in 50% of sporadic diffuse-type gastric cancers (Becker 
et al., 1994, 1999; Ascano et al., 2001; Fricke et al., 2003). Loss of CDH1 function is associated 
with the invasion activity of tumor cells, which is related to reduction of cell adhesion and/or 
the signalling pathways in which CDH1 is involved [(Berx et al., 1998) and references therein]. 
E-cadherin mutation is suggested to be an early event in tumorigenesis [(Berx et al., 1998) and 
references therein].
Transforming growth factor  (TGFB, 19q13) is a growth inhibitor of epithelial cells [see review 
(Derynck et al., 2003)]. TGFB regulates transcription through the Smad pathway [see review 
(Derynck et al., 2003)]. TGFB also activates other signalling reactions, e.g., ERK, JNK, and MAPK 
(mitogen activated protein kinase) kinase pathways [see review (Derynck et al., 2003)]. Mutations 
have been found in Smad pathway genes in TGFB type II receptor and the SMAD4 in gastric 
cancer cell lines (Park et al., 1994; Yang et al., 1999; Ju et al., 2003).
Recently, the runt-related transcription factor 3 (RUNX3) gene has been implicated in gastric 
cancer. RUNX3 belongs to the family of RUNX transcription factors and is a target of TGFB-
superfamily signalling (Lee et al., 2002c; Ito et al., 2003). A silenced RUNX3 gene has been detected 
in 40% to 60% of the gastric tumors [see review (Lund et al., 2002)], (Li et al., 2002). RUNX3 has 
been suggested to function in the development of the gastrointestinal tract [see review (Lund et 
al., 2002)]. 
The most frequent alterations detected in tumor supressor genes are summarized in Table 4.
Table 4. Frequently detected tumor suppressor genes in gastric carcinoma
Gene Chromosomal 
location
Frequently found 
chromosomal 
loss by CGH/
allelic loss
LOH/ 
deletion 
Loss of 
mRNA/ 
protein 
expression
Protein 
accumulation
Somatic 
mutation
Methylation
p53 17p13 yes 17-91% 0-77%
PTEN 10q23 no 20% 39%
APC 5q21 yes ? ? 4%
DCC 18q21 yes 35% 49%
CDH1 16q22 no ? 50%
RUNX3 1p36 no 30% 45-60% ? ?
18
4.5 Mismatch repair genes involved in gastric carcinoma
In human cells, mismatch repair (MMR) proteins eliminate such DNA errors as single base 
mismatches and insertion-deletion loops that may appear during replication  [see review 
(Peltomaki, 2003). Repeated sequences, such as microsatellites, are especially susceptible to 
mutations (microsatellite instability, MSI). Loss of function of mismatch repair gene/s through 
mutation or hypermethylation causes partial or complete inactivation of the repair process. This 
increases genomic instability and, accordingly, raises carcinogenic risk [see review (Peltomaki, 
2003)]. Germline mutations of MMR genes are well-known in hereditary nonpolyposis colon 
cancer [see review (Peltomaki, 2003). 
MSI is observed in 10 to 40% of sporadic gastric cancer cases (Lee et al., 2002a), [(Leung 
et al., 1999) and references therein]. Loss of human mutL homologue 1 (hMLH1) protein and 
hypermethylation of the hMLH1 promoter are associated with in high-MSI gastric cancer (Leung 
et al., 1999; Bevilacqua et al., 2000).
4.6 E-cadherin in hereditary diffuse adenocarcinoma
Only a small proportion, 1 to 2%, of gastric cancers develop as a result of inherited syndromes 
with predispositions to gastric cancer, for example, hereditary diffuse gastric cancer syndrome 
(HDGC), hereditary nonpolyposis colon cancer syndrome, Peutz-Jeghers syndrome or Li-
Fraumeni syndrome (germline mutation of p53) [(Grady et al., 2002) and references therein]
E-cadherin (CDH1) germline mutations have been reported only in diffuse-type gastric cancer 
(HDGC), ﬁ rst in Maori families (Guilford et al., 1998). In the CDH1 gene, 14 germline truncating 
mutations have been found in families with HDGC to date [see review (Caldas et al., 1999)]. 
Mutations in CDH1 has been estimated to affect only 25% of families fulﬁ lling the HDGC criteria 
established by the First Workshop of the International Gastric Cancer Linkage Consortium [see 
review (Caldas et al., 1999)], (Ascano et al., 2001; Avizienyte et al., 2001). 
5. DNA COPY NUMBER CHANGES AND GENETIC ALTERATIONS IN BARRETT 
ADENOCARCINOMA
Only a small number of cytogenetic and genetic studies of Barrett adenocarcinoma have been 
published to date. Allelic losses have been mapped to the tumor suppressor gene p53 (Dunn et al., 
1999) at 17p and to chromosomal regions 4q, 5q and 18q (Hammoud et al., 1996; Wu et al., 1998). 
Losses at 17p and 18q have been suggested to predict poorer prognosis (Wu et al., 1998).
Some genetic similarities and differences have been found between xenografts of 
adenocarcinomas arising from Barrett esophagus and adenocarcinomas of gastric origin (El-Rifai 
et al., 2001). In xenografted Barrett adenocarcinoma, the most common gains were detected at 17q 
(11/12, 92%) and 20q (12/12, 100%), and losses in chromosomes 4 (12/12, 100%) and 5 (10/12, 
83%). Gains at 17q and losses at 4q and 14q were more frequent in Barrett adenocarcinoma than 
in distal tumors. In addition, these changes were more common in proximal tumors than in distal 
tumors (El-Rifai et al., 2001). The xenograft study also suggested that gains at 2q, 6p, 12p, and 
20q and losses at 5q and 8p are more frequent in Barrett adenocarcinoma than in other proximal 
tumors (El-Rifai et al., 2001). 
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In 30 primary tumors of Barrett adenocarcinoma, frequent chromosomal gains were found at 
8q (80%), 20q (60%), 2p (47%), 6p (37%), 15q (33%), and 17q (30%), and losses at Y (76%), 4q (50%), 
5q (43%), 9p (43%), 18q (40%), 7q (33%), and 14q (30%) (Walch et al., 2000). 
In a study of Barrett adenocarcinoma and its premalignant stages (metaplasia, low-grade 
dysplasia, high-grade dysplasia), the 17q gain was detected in high-grade dysplasia (Riegman 
et al., 2001). These ﬁ ndings suggest that 17q ampliﬁ cation arises from dysplastic mucosa during 
pathogenesis.
LOH, mutation, or hypermethylation of the promoter have been detected in genes that block 
Rb phosphorylation, such as p16, p53, tumor suppressor gene APC, and E-cadherin. E-cadherin is 
implicated in the progression of metastasis [reviewed in (Morales et al., 2002; Wild et al., 2003)]. 
Upregulation of growth the signalling molecules cyclin D1 and E, EGFR, TGF, and TNF (tumor 
necrosis factor) have been linked to tumorigenesis of Barrett adenocarcinoma [reviewed in 
(Morales et al., 2002; Wild et al., 2003)]. Increased expression has also been detected in the vascular 
endothelial growth factor (VEGF) genes that affect angiogenesis [reviewed in (Morales et al., 2002; 
Wild et al., 2003)]. Overexpression of COX-2 protein has observed in Barrett metaplasia, dysplasia 
and adenocarcinoma (Shirvani et al., 2000). In Barrett adenocarcinoma patients, high expression of 
COX-2 is associated with a more aggressive course of disease (Buskens et al., 2002).
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AIMS OF THE STUDY
• to investigate genetic alterations in Barrett adenocarcinoma 
• to investigate genetic changes in younger (≤ 45 years of age) gastric carcinoma patients
• to characterize the frequently ampliﬁ ed chromosomal region of 17q
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MATERIAL AND METHODS
1. MATERIAL
Most of the primary tumor samples studied were from Finnish patients, with the exception of 
study II where some of the tumor samples were from Dutch patients. All were obtained during 
routine diagnostic procedures. Frozen primary tumors were collected during the years 1998 to 
2002 and parafﬁ n-embedded samples were collected during 1983 to 2002. In addition to primary 
tumors, cell lines and xenografts were studied. 
In study I, parafﬁ n-embedded tumor specimens from 18 Barrett adenocarcinoma patients were 
provided by the Departments of Pathology at the Helsinki University Central Hospital and the 
Central Hospital of Central Finland. The samples were analyzed by CGH. Classiﬁ cation criteria 
for deﬁ ning tumors as Barrett adenocarcinoma were adenocarcinoma in the lower esophagus or 
gastro-esophageal junction with concomitantly or previously veriﬁ ed Barrett metaplasia in the 
distal esophagus. The mean age of Barrett adenocarcinoma patients was 64 years (range 52-73). 
Five, ten, and three of the tumors were at stages I, II and III, respectively. 
 In study II, specimens from 24 gastric carcinoma patients and three gastric cancer cell lines 
from patients aged 45 years or younger were examined in Study II. Tumor specimens were 
obtained from the Departments of Pathology at the Helsinki University Central Hospital, the 
Jorvi Hospital (Espoo), and the Academic Medical Center (Amsterdam, Netherlands). Fifteen 
of the tumors were intestinal-type gastric cancer, seven were diffuse-type and two were mixed-
type. The mean age of young gastric cancer patients was 39 years (range 18-45 years). Tumor 
samples were classiﬁ ed as early or advanced carcinomas. Twenty-three samples were advanced 
carcinoma and only one sample was early carcinoma. Gastric cancer cell lines were provided by 
the Hiroshima University School of Medicine and Fukushima Medical College (Japan).   
Twenty-two tumors and three cell lines were investigated with CGH (parafﬁ n-embedded 
tumor specimens), eight cases with ﬂ uorescence in situ hybridization (FISH) (parafﬁ n-embedded 
tumor specimens, same cases as in the CGH study), six tumors and three cell lines with Southern 
blotting (frozen primary tumors, four of the same cases as in the CGH study while two of these 
cases only by Southern blot) and four tumors by immunohistochemistry (IHC) (same cases as in 
the CGH study, two intestinal with a 19q amplicon and two diffuse with a normal CGH result). 
In study III, ten parafﬁ n-embedded specimens from gastric carcinoma patients and one 
normal stomach tissue sample were obtained from the Department of Pathology at the Helsinki 
University Central Hospital. Seven of the tumors were intestinal-type gastric cancer and three 
were diffuse-type. Ampliﬁ cations of ERBB2 and gastrin (GAS) genes were studied by FISH with 
gene-speciﬁ c probes. Seven of the tumors had an amplicon at the 17q region and three a normal 
CGH proﬁ le (Kokkola et al., 1997). In addition to the tumor samples, two gastric cancer cell lines 
and 40 breast cancer cell lines were included in the FISH study. Cell lines were purchased from the 
American Type Culture Collection (Rockville, MD, USA) and the Arizona Cancer Center’s Cell 
Culture Core Facility (Tucson, AZ, USA), and eleven cell lines were provided by the University of 
Michigan Medical School (Stephen P. Ethier, Ann Arbor, MI, USA).
In study IV, six gastric carcinoma xenografts (two intestinal, one diffuse, one mixed, and 
two of unknown type), two Barrett adenocarcinoma xenografts and three gastric cancer cell 
lines were included in the DNA copy number study using complementary DNA (cDNA) 
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microarray. Six gastric carcinoma xenografts (four intestinal, and two of unknown type), two 
Barrett adenocarcinoma xenografts and three gastric cancer cell lines were included in the gene 
expression study using the same cDNA-array. Material from three xenografts were used in both 
cDNA-array studies, material from another ten xenografts were included in the DNA copy 
number study (ﬁ ve xenografts) and the gene expression study (ﬁ ve xenografts). Gastric cancer 
cell lines (CRL-5822, CRL-5974, and CRL-5973) were included in both studies. 
In addition, six frozen primary gastric cancer tumors and seven xenografts were included in 
a multiplex polymerase chain reaction (PCR) experiment. The cell lines were purchased from the 
American Type Culture Collection and the xenografts were obtained from the Digestive Health 
Center of Excellence (Wa’el El-Rifai, University of Virginia, Charlottesville, VA, USA). The results 
were conﬁ rmed by Northern blot with three cell lines, and by reverse transcriptase (RT)-PCR with 
seven xenografts and six primary tumors. 
As reference samples, we used normal genomic DNA for the CGH-array, for the cDNA-array a 
pool of normal gastric epithelial samples (four cases), for Northern blot a normal gastric epithelial 
sample and gastric cancer cell line (CRL-1739), and for multiplex PCR a pool of normal gastric 
epithelial samples. Epithelial reference samples were randomly chosen. The gastric cancer cell 
line CRL-1739 had normal copy numbers, as revealed by CGH.
In Study V, the gastric cancer tumor tissue array was prepared using 78 specimens of gastric 
carcinoma tumors and specimens from four different normal gastric epithelial tissues. Parafﬁ n-
embedded specimens for the tumor array were obtained from the Department of Pathology at 
the Helsinki University Central Hospital. Specimens for the tumor tissue array were chosen from 
representative prospectively collected parafﬁ n-embedded sections. In situ hybridization and 
immunohistochemical staining were performed on the tumor tissue array. Gastric carcinoma 
tumors were analyzed using three gene-speciﬁ c probes for ERBB2, TOP2A, and DARPP32 
(dopamine-and cAMP-regulated phosphoprotein, 32 kD) by in situ hybridization (ﬁ fty-two were 
analyzable, forty intestinal, twelve diffuse). In the immunohistochemistry experiment antibodies 
speciﬁ c to DARPP32 and ERBB2 were used (sixty-six cases were analyzable, forty-ﬁ ve intestinal, 
twenty-one diffuse). The mean age of gastric carcinoma patients was 68 years (range 47-88) in in 
situ hybridization (ISH) study and 66 years (range 47-88) in IHC study. In the ISH study twenty, 
fourteen, twelve and six of the tumors were at stages I, II, III and IV, respectively. In IHC study 
twenty-four, nineteen, ﬁ fteen and eight of the tumors were at stages I, II, III and IV, respectively. 
Twenty-nine frozen primary gastric carcinoma specimens were studied by quantitative 
real-time PCR with ERBB2, TOP2A, and DARPP32 primers to reveal expression levels of these 
genes. Fourteen cases were of intestinal-type gastric cancer, fourteen of diffuse-type and one was 
of mixed-type. The specimens were obtained from the Department of Surgery at the Helsinki 
University Central Hospital. As references in real-time PCR we used four normal gastric epithelial 
samples. The mean age of patients was 69 years (range 38-91). Two cases were at stage I, and nine 
each at stages II, III and IV.
The patient series for the tumor tissue array and real-time PCR were different. The specimen 
and method information used in each study is summarized in Table 5.
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Table 5.  Number, tumor types, and histological subtype of tumors, cell lines and xenografts included in 
the studies, the methods used in each study and the origin of the samples. Reference samples or 
cell lines are not included in the table.
Study Number of 
studied tumors, 
cell lines or 
xenografts
Tumor type and histological 
subtype
Methods Origin 
I 18 tumors Barrett adenocarcinoma CGH HUCH
CHCF
II 24 tumors
3 cell lines*
TMK-1
MKN-7
MKN-74
Gastric carcinoma, patient aged ≤ 45
15 intestinal, 7 diffuse, 2 mixed
Poorly differentiated
Well differentiated
Well differentiated
CGH, FISH (19q12 speciﬁ c), 
Southern blot 
(CCNE, CEBPA, TGFB, 
BCL3, AKT2)
IHC (CCNE)
HUCH
AMC 
III 10 tumors
cell line
CRL-5822
Gastric carcinoma, 7 intestinal, 3 
diffuse
Well differentiated
FISH (ERBB2, GAS)
Western blot (ERBB2, GAS)
HUCH
ATCC
IV 8 xenografts 
(CGH-array) 
8 xenografts 
(cDNA-array) 
3 cell lines
CRL-5822
CRL-5974
CRL-5973
7 xenografts 
and 6 primary 
tumors (RT-
PCR)
Xenografts: 3 Barrett 
adenocarcinoma, 5 intestinal, 1 
diffuse, 1 mixed, 3 no information
Cell lines: 
Well differentiated
poorly differentiated
poorly differentiated
Chr 17- speciﬁ c cDNA-array,
Northern blot (DARPP32, 
TOP2A, ERBB2)
RT-PCR  (DARPP32, TOP2A)
DHCE
ATCC
DHCE
V  78 tumors
(Gastric cancer 
tumor tissue 
array)
29 tumors
(QRT-PCR)
A) 52 analyzed by ISH 
 40 intestinal, 12 diffuse 
B) 66 analyzed by IHC 
 45 intestinal, 21 diffuse
Gastric cancer, 14 intestinal, 14 
diffuse, 1 mixed
ISH (DARPP32, ERBB2, 
TOP2A)
IHC (DARPP32, ERBB2)
Quantitative Real-Time PCR
(DARPP32, ERBB2, TOP2A)
HUCH
HUCH, Helsinki University Central Hospital, Helsinki
CHCF, Central Hospital of Central Finland, Jyväskylä
AMC, Academic Medical Center, Amsterdam, Netherlands
ATCC, American Type Culture Collection, Manassas, VA, USA
DHCE, Digestive Health Center of Excellence, University of Virginia, Charlottesville, USA
* The cell lines were obtained from the Hiroshima University School of Medicine and 
Fukushima Medical College, Japan
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2. METHODS
2.1 Comparative genomic hybridization (Studies I and II) 
CGH was performed on Barrett adenocarcinoma samples (Study I), young gastric carcinoma 
samples, and cell lines of young patients (Study II) to determine DNA copy numbers according 
to the protocol described by Kallioniemi et al. (1992, 1994), with slight modiﬁ cations (El-Rifai et 
al., 1997).
DNA was extracted from histological sections of representative tumor tissues and cell 
lines using a standard protocol. Tumor DNA was labeled with ﬂ uorescein isothiocyanate 
(FITC)-dCTP and FITC-dUTP (DuPont, Boston, MA, USA) by nick-translation. The reference 
DNA was extracted from peripheral blood samples of healthy men and women and similarly 
labeled with Texas-red dCTP and Texas-red dUTP (DuPont). Evaluation was performed with 
gel electrophoresis, the lengths of the labeled fragments ranged between 600-2000 base pairs. 
A mixture of test DNA (1 µg), reference DNA (1 µg), and unlabeled Cot-1 DNA (20 µg), to block 
the binding of repetitive sequences, was precipitated with 1/10 volume of 3 M sodium acetate 
and 9 volumes of absolute ethanol at Ð20°C overnight. The DNAs were dissolved in 15 µl of 
hybridization buffer [50% formamide/10% dextran sulfate/2 x SSC (standard saline citrate, pH 
7)] at 37°C. Metaphase preparation slides were denaturated at 65°C in 70% formamide/2 x SSC 
(pH 7) for 2 minutes. The DNA hybridization mixture was denatured for 5 minutes at 75°C and 
applied to the slides. The hybridization was performed in a moist chamber at 37°C for two days. 
Posthybridization washes were performed at 45°C for 5 minutes three times in 50% formamide/
2 x SSC (pH 7), twice in 2 x SSC (pH 7), and once in 0.1 x SSC (pH 7) followed by 2 x SSC for 10 
minutes, PN buffer [0.1 M NaH2PO4/0.1 M Na2HPO4/0.1% Nonidet P40 (pH8)] for 20 minutes, 
and distilled water at room temperature. Finally the slides were mounted with an antifading 
medium containing counterstain 4’,6’-diamidino-2-phenylindole (DAPI) (Vectashield; Vector 
Laboratories Inc., Burlingame, CA, USA). 
The slides were analyzed with an Olympus ﬂ uorescence microscope and the ISIS digital image 
analysis system (MetaSystems GmbH, Altlussheim, Germany), which includes an integrated 
high-sensitivity monochrome charge-coupled device (CCD) camera and automated CGH analysis 
software. From each case, images of 8 to 12 metaphases of good quality with strong uniform 
hybridization were captured in three colors. The chromosomes not suitable for the analysis were 
ignored, i.e., overlapping or strongly bent chromosomes, centromeric regions of chromosomes 1, 
9 and 16, short arms of acrocentric chromosomes and the entire chromosome Y. These particular 
regions contain large amounts of heterochromatin. The intensity ratios of green and red colors 
were measured along each chromosome. If no copy number changes were found the green-to-
red ratio was 1. A ratio exceeding 1.17 was considered as gain of the chromosomal region and a 
ratio below 0.85 was considered as loss. High-level ampliﬁ cation was considered when the ratio 
exceeded 1.5. The cut-off values were deﬁ ned by negative control experiments using two normal 
DNA samples hybridized onto the same preparation. Conﬁ rmation was performed using 99% 
conﬁ dence intervals for the ratio proﬁ le and by estimating the error probability.
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2.2 Nuclei extraction (Study II and III) 
The nuclei from parafﬁ n-embedded tissue were extracted for FISH analysis in Studies II and III 
according to protocols described by others (Heiden et al., 1991; Hyytinen et al., 1994), with slight 
modiﬁ cations. Ten 10 µm sections were deparafﬁ nized and incubated in 1 ml of Carlsberg’s 
solution (0.1% Sigma protease XXIV, 0.1 M Tris, 0.07 M NaCL, pH 7.2) for 1 hour at 37°C then 
vortexed for 20 minutes. The nuclear suspension was ﬁ ltered through nylon mesh with pore size 
55 µm, centrifuged, and diluted in 0.1 M Tris. The nuclei suspension was spread onto slides and 
examined microscopically.
2.3 Interphase ﬂ uorescence in situ hybridization with probes speciﬁ c to 19q12 (Study II), 
GAS, and ERBB2 (Study III)
In study II, the gain at 19q detected with CGH was conﬁ rmed by FISH analysis with a 19q12 
speciﬁ c probe. In study III, GAS and ERBB2 ampliﬁ cation were studied in gastric carcinoma 
tumors using FISH.
Probes were labeled with biotin-14-dATP or digoxigenin-dUTP (Gibco BRL) by nick-
translation, precipitated with herring sperm DNA (0.62 µg/µl, Sigma) and human Cot-1 DNA 
(0.62 µg/µl, Gibco BRL) and dissolved in hybridization buffer (50% formamide, 20% dextran 
sulfate, 2 x SSC).  The slides were incubated in 1 M sodium thiocyanate at 70°C for 15 minutes, 
followed by treatment with 0.05 N HCl at 37°C for 10 minutes, then 5 mg/ml pepsin in 0.05 N HCl 
at 37°C for 15 minutes. The slides were dehydrated in a rising alcohol series (70%, 85%, 100%) and 
denatured in 70% formamide/2 x SSC, pH 7, at 75°C for 5 minutes, followed by dehydration in a 
cold alcohol series. The probes were denatured at 75°C for 5 minutes and applied onto the slides. 
Hybridization was performed at 37°C for two days. Posthybridization washes were performed 
at 45°C three times in 50% formamide, pH 7, once in 2 x SSC, pH 7, twice in 0.1 x SSC, pH 7, 
for 5 minutes each and once in 4 x SSC/0.2% Tween (Sigma), pH 7, at room temperature for 5 
minutes. For signal detection in one color FISH, the slides hybridized with biotin-labeled probe 
were treated with FITC-conjugated avidin (Vector Laboratories), followed by signal ampliﬁ cation 
with anti-avidin D/avidin-FITC (Vector Laboratories). In dual-color FISH the biotin-labeled 
probes were detected by incubatig slides with avidin -tetra-rhodamine-isothiocyanate (TRITC) 
(Vector Laboratories), and the signals were ampliﬁ ed by biotinylated anti-avidin solution (Vector 
Laboratories) and avidin-TRITC. The digoxigenin-labeled probes were visualized by treatment 
with mouse anti-digoxigenin (Boehringer Mannheim Gmbh, Mannheim, Germany), rabbit 
anti-mouse FITC (Sigma) and goat anti-rabbit FITC (Sigma). Finally the slides were mounted 
with an anti-fade solution containing DAPI counterstain (Vector Laboratories). From each slide 
a minimum of 100 morphologically intact and nonoverlapping nuclei were examined with an 
Olympus ﬂ uorescence microscope.
2.4 Southern blot (Study II)
In Study II, gene copy number changes in the frequently ampliﬁ ed chromosomal region of 19q 
were characterized by Southern blots in six young gastric cancer patients and three cell lines. 
Genomic DNA was digested, size selected in agarose gel, blotted onto nylon ﬁ lters (Amersham 
Pharmacia Biotech, Uppsala, Sweden) and hybridized with gene probes for CCNE, CEBPA, TGFB, 
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BCL3, and AKT2 (image clones from RZPD, Berlin, Germany).  The results were analyzed using 
a phosphorimager (Fuji, Kanagawa, Japan) and the AIDA software. DNA from normal gastric 
tissues was served as a reference.
2.5 Immunohistochemistry (Studies II and V) 
In study II, overexpression of the CCNE protein in young gastric cancer patients with the 19q 
amplicon (Study II) was conﬁ rmed by immunohistochemistry using the monoclonal antibody 
CYE5 (Neomarkers, Fremont, CA, USA) at 1:40 dilution. Two cases with and two cases without 
the 19q amplicon were investigated. The immunostaining was performed on deparafﬁ nized 4 
µm sections. The slides were treated in 0.3% H2O2 in methanol for 20 minutes and subjected to 
heat treatment at 100°C in TE (pH 9) for 10 minutes. Non-speciﬁ c binding sites were blocked by 
incubation in 5% normal goat serum for 10 minutes. The preparations were incubated with the 
primary antibody at room temperature and visualized with the Powervision+poly-HRP detection 
system (ImmunoVision Technologies).
In Study V, DARPP32 and ERBB2 protein expression levels were studied by 
immunohistochemistry. DARPP32 immunostaining was performed on 4 µm sections of tumor 
tissue array. Sixty-six cases were analyzed. After microwave treatment in citrate buffer for 20 
minutes, the rabbit anti-DARPP32 antibody (H-62, Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA) was applied at 1:200 dilution and the preparation was incubated at room temperature. 
The avidin-biotin immunoperoxidase method was used in detection. Expression of the DARPP32 
protein was scored as 0 (no positive cells), 1+ (1-33% positive cells), 2+ (34-66% positive cells) or 
3+ (67-100% positive cells).
Immunohistochemical analysis of ERBB2 in Study V was performed on 4 µm sections using 
the monoclonal antibody cerbB-2 (Novocastra Laboratories, Newcastle upon Tyne, UK) at 1:500 
dilution for 30 minutes. Slides were pretreated by microwaving in TrisEDTA buffer (pH 9) for 20 
minutes. Immunostaining was performed with the EnVision/DAB detection kit (DakoCytomation, 
Glostrup, Denmark) in an automatic immunostaining system (LabVision, Freemont, CA, USA).
2.6 Western blot (Study III)
In Study III, protein expression of ERBB2 and GAS was studied by Western immunoblot in 
two gastric cancer cell lines, CRL-5822 and CRL-7873, a breast cancer cell line (BCF-715) and 
normal reactive lymphatic tissue as a reference sample. Protein concentration was determined 
using a BSA protein assay (Pierce, Rockford, IL, USA). Equal amounts of protein from each cell 
lysate were electrophoresed in a 12.5% sodium dodecylsulfate-polyacrylamide gel and blotted 
onto nitrocellulose ﬁ lters. Detection of immobilized ERBB2 and GAS proteins were performed 
according to standard procedures with polyclonal antibodies (dilutions 1:1000 for ERBB2 and 1:
250 for GAS; Dako A/S, Copenhagen, Denmark) with enhanced chemiluminescence detection 
(Amersham, Buckinghamshire, UK).
2.7 Chromosome 17-speciﬁ c cDNA array (Study IV)
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2.7.1 Chromosome 17-speciﬁ c cDNA array construction and preparation
In study IV, a chromosome 17-speciﬁ c cDNA array was used for comprehensive characterization 
of ampliﬁ ed and overexpressed target genes at the 17q region.
Construction, clone selection, and preparation of the chromosome 17-speciﬁ c cDNA microarray 
are described in detail in Monni et al. (2001). The microarray was ﬁ rst designed for a breast cancer 
study, and contained a total of 636 transcripts, including 201 known genes from chromosome 17 
and 435 expressed sequence tags (ESTs), mapping to intervals D17S933-D17S930 (293-325 cR, the 
17q12-q21 region) and D17S791-D17S795 (333-435 cR, the 17q23-q24 region). Additionally, the 
microarray contained 88 housekeeping genes. 
The preparation and printing of target DNA onto a glass slide was performed according to 
the protocols of DeRisi et al. (1996) and Shalon et al. (1996). The image consortium clones were 
obtained from Research Genetics Inc. (Huntsville, AL, USA) and were provided as Escherichia coli 
cultures in 96 well-plates. The clones were pre-grown to reach the maximum plasmid production. 
The plasmid DNA was isolated using the 96 well alkaline lysis MiniPrep kit (Edge BioSystems, 
Gaithersburg, MD, USA), and the DNA used as a template for PCR ampliﬁ cation of the cDNA 
inserts with M13 primers. The PCR products were puriﬁ ed using ethanol/acetate precipitation. 
Pre-cleaned glass slides were coated with poly-L-lysine solution (Sigma, St. Louis, MO, USA). 
In the printing process, puriﬁ ed PCR products were deposited onto the slides by a custom-built 
arraying robot. After printing, the slides were kept at room temperature for one week. DNA was 
ﬁ xed to the slides by UV-crosslinking with a 450 mJ dose by Stratalinker (Stratagene, La Jolla, 
CA, USA). Finally, the slides were rinsed in blocking solution (70 mM succinic anhydride/0.1 M 
boric acid, pH 8.0/35% 1-methyl-2-pyrrolidinone; Aldrich Chemical Co., Milwaukee, WI, USA) 
to reduce non-speciﬁ c binding of strongly negatively charged probes on positively charged 
amine groups on the poly-L-lysine coated slides. After succinic anhydride treatment, the DNA 
was denatured by boiling the slides in water for 2 minutes. Denaturation was followed by 100% 
ethanol treatment for 1 minute and centrifugation to dry the slides. The slides were allowed to dry 
for one night in a dust-free cabinet at room temperature prior to hybridization.
2.7.2 Probe labeling and hybridization
2.7.2.1 DNA samples
Genomic DNA was isolated from three gastric cancer cell lines (CRL-5822, CRL-5973, CRL-5974) 
and eight xenografts (X11, X27, X57, X71, X75, X79, X83, X95) to investigate DNA copy number 
changes in chromosome 17 by cDNA array. All cases included in this analysis had gains or high-
level ampliﬁ cations at the 17q region, as revealed by CGH (El-Rifai et al., 2001, unpublished 
data). 
 Probe labeling and hybridization were performed as described by Monni et al. (2001) and 
Pollack et al. (1999), and posthybridization washes as described by Mousses et al. (2000).  In the 
CGH array, normal genomic DNA (20 µg) as a reference, was digested with restriction enzymes 
AluI and RsaI (Life Technologies, Inc., Rockville, MD, USA) and puriﬁ ed by phenol/chloroform 
extraction. Digested test DNA (6 µg) was labeled with Cy3-dUTP (Amersham Biosciences, 
Piscataway, NJ, USA) and reference DNA (6 µg) with Cy5-dUTP using the Bioprime labeling kit 
(Life Technologies). The hybridization mixture consisted of labeled probes, human Cot-1 DNA 
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(30-50 µg; Gibco BRL, Life Technologies, Rockville, MD, USA), yeast tRNA (100 µg, Gibco BRL), 
poly dA, and poly dT (20 µg, Sigma) in 3.4 x SSC/0.3% SDS. Probes were denaturated at 100°C 
for 1.5 minutes, annealed at 37°C for 30 minutes, and hybridized to the array under a coverslip at 
65°C for 16 hours. After hybridization the arrays were washed in 0.1% SDS, 0.5 x SSC/0.01% SDS 
and 0.06 x SSC for 2 minutes each at room temperature. 
2.7.2.2 RNA samples
Total RNA was extracted from three gastric cell lines (CRL-5822, CRL-5973, CRL-5974) and 
eight xenografts (X43, X49, X57, X68, X75, X76, X80, X95) to evaluate mRNA expression levels in 
chromosome 17. Six of the xenografts (X49, X57, X68, X75, and X76) and all three cell lines had 17q 
gains and two of the cases (X43 and X80) had no detectable gains (El-Rifai et al., 2001, unpublished 
data). Reference RNA was extracted from four different normal gastric epithelial specimens and 
pooled. 
The hybridization protocol was as described by Khan et al. (1998) and Mousses et al. (2000). 
Reference RNA (100 µg) was labeled with Cy5-dUTP and test-RNA (70 µg) with Cy3-dUTP by 
oligode oxythymidylate-primed polymerization using SuperScript II reverse transcriptase (Life 
Technologies) The hybridization mixture consisted of labeled probes, poly dA (8 µg; Sigma), E. 
coli tRNA (4 µg; Sigma), Cot 1 DNA (10 µg; Gibco BRL) and 3 x SSC/0.1% SDS. The probe was 
denaturated at 98°C for 2 minutes, cooled on ice for 10 seconds and hybridized on the array under 
a coverslip at 65°C for 16 hours. The slides were washed in 0.1% SDS, 0.5 x SSC/0.01% SDS, and 
0.06 x SSC for 2 minutes each at room temperature.
2.7.3 Analyses of DNA copy number changes and expression by cDNA microarrays
DNA copy number and expression changes were analyzed according to the protocol described 
by Monni et al. (2001) and Pollack et al. (1999). The ﬂ uorescence intensities of test and reference 
hybridizations were scanned separately and measured with a confocal laser scanner (Agilent 
Technologies Palo Alto, CA, USA). The data were analyzed by the DEARRAY software (Chen 
et al., 1997). Background intensity was subtracted, and the average intensities of each spot in the 
test hybridization (red) were divided by the average intensity of the same spot in the control 
hybridization (green). Normalization was based on the 88 housekeeping genes to calculate the 
calibrated ratio for each cDNA spot. The threshold values for ampliﬁ cation and overexpression 
ratios were based on previous reports by Monni et al. (2001) and Kauraniemi et al. (2001). A Copy 
number ratio ≥ 1.5 was considered as ampliﬁ ed, and expression ratio ≥ 3.0 as overexpressed. 
2.8 Northern blot (Study IV)
The cDNA microarray results were validated by Northern blot in Study IV. Total RNA was 
extracted from four cell lines (CRL-5822, CRL-5973, CRL-5974, CRL-1739) and two normal 
stomach tissues using the RNAeasy kit (Qiagen GmbH, Hilden, Germany). Isolated RNA was 
size-selected in an agarose gel containing formaldehyde and blotted onto a nylon membrane 
(Schleicher & Schuel, Keene, NH, USA). Sequence-veriﬁ ed cDNA inserts for DARPP32 (EST 
AA552509), TOP2A, and ERBB2 were labeled with P32 by random priming (Prime-It, Stratagene). 
Glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was used as a control probe. The 
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membrane was prehybridized with sheared herring sperm (10 µg/ml; Research Genetics) and 
hybridized in Express hybridization solution (Clontech, Palo Alto, CA, USA).
2.9 Tumor tissue array (Study V)
In study V, gene ampliﬁ cation of DARPP32, TOP2A, and ERBB2 in gastric carcinoma samples was 
investigated using the tumor tissue array. In addition, protein expression of DARPP32 and ERBB2 
was studied with the same tumor tissue array.
For the tumor tissue array, a total of 78 archival parafﬁ n-embedded gastric cancer specimens 
and ﬁ ve normal gastric epithelial samples were veriﬁ ed and representative areas were selected 
using hematoxylin and eosin staining. Tissue biopsies (0.6 mm) were taken from the selected 
donor regions and punched onto the recipient block with a manual tissue array instrument 
(Beecher Instruments, Silver Springs, MD, USA). Normal gastric epithelial samples were punched 
in each sample row as controls and each tumor sample was punched in duplicate. Sections of 
5 µm were cut and transferred to the polylysine-coated slides for in situ hybridization and 
immunohistochemical analyses.  
2.10 In situ hybridization of the tumor tissue array (Study V)
Tumor tissue array sections were pre-treated prior to in situ hybridization in a microwave oven 
in 0.01 M citric acid at 92°C for 10 minutes to remove parafﬁ n. Slides were rinsed in PBS and 
digested with pepsin solution (Digest-All 3; Zymed Laboratories Inc., South San Francisco, CA, 
USA) at 37°C for 10 minutes. After digestion slides were rinsed in PBS, dehydrated in a graded, 
rising ethanol series and ﬁ nally air dried.
Spot-Light chromosome 17 centromeric probe (Zymed), Spot-Light HER2 probe (Zymed), 
Spot-Light Topoisomerase 2 alpha probe (Zymed), and sequence-veriﬁ ed BAC clone CTD-
2019C10 (Research Genetics) for DARPP32 were used in the in situ hybridization study. 
The Zymed probes were hybridized following the supplier’s protocol. The probe was applied 
onto the slides, which were then coverslipped and sealed with rubber cement and denatured 
at 98°C on a hot plate for 5 minutes. Hybridization was performed at 37°C for two days. After 
hybridization the slides were washed in 0.5 x SSC at 73°C for 5 minutes, three times in PBS, 
0.025% Tween at room temperature, and blocked with blocking solution (CAS Block; Zymed) for 
10 minutes at room temperature. 
For the TOP2A and 17 centromeric probe signal detection, the slides were incubated with anti-
digoxigenin-ﬂ uorescein Fab fragments (40 µg/ml in PBS/0.5% BSA) (Roche Diagnostics Gmbh, 
Mannheim, Germany) at 37°C for 10 minutes, washed three times in PBS for 2 minutes and 
mounted. The ERBB2 signal was detected with the speciﬁ c HRP-based PowerVision Histostaining 
Kit (ImmunoVision Technologies, Co., Daly City, CA, USA). The slides were incubated in solution 
with mouse anti-digoxigen (Boehringer Mannheim GmbH, Mannheim, Germany) and blocking 
solution (ImmunoVision Technologies) at room temperature for 30 minutes, washed three times 
in PBS for two minutes, following incubation with polymerized HRP-goat anti-mouse IgG for 
30 minutes and equal PBS washes. The presence of peroxidase was detected by addition of DAB 
substrate-chromogen solution for 5 minutes. The slides were rinsed in water and the tissue 
samples stained with hematoxylin.
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The DARPP32 probe was labeled with biotin-14-dATP by nick-translation, and denaturation, 
hybridization, and detection were performed as described in section 2.3.
Analyses of the tumor-array preparations were performed using a Zeiss Axiophat ﬂ uorescence 
microscope (ﬂ uorescence labeled arrays) and an Olympus BH-2 light microscope.  A minimum of 
100 nonoverlapping nuclei were scored for each sample.
2.11 Polymerase chain reaction (Studies IV and V)
2.11.1 Multiplex RT-PCR (Study IV)
The cDNA array results for the two most overexpressed genes, DARPP32 and TOP2A were 
conﬁ rmed by multiplex RT-PCR. RT-PCR was performed according to standard protocol for 28 
cycles using seven xenografts, six primary gastric cancer samples, and a pool of normal gastric 
epithelial tissues obtained from different individuals. 
2.11.2 Quantitative real-time PCR (Study V)
mRNA expression levels of DARPP32, TOP2A, and ERBB2 in 29 gastric cancer samples and four 
normal epithelial samples were examined using the quantitative real-time PCR method (Roche 
Diagnostics GmbH). The tumor specimens were trimmed to contain more than 50% tumor cells. 
Primers were designed for DARPP32, TOP2A, and ERBB2 (TIB Molbiol, Berlin, Germany) and B-
actin was used as a reference housekeeping gene. Isolated RNA (Qiagen GmbH) was synthesized 
for single-stranded cDNA (First Strand cDNA Synthesis Kit; Roche Diagnostics GmbH). The 
quantitative real-time PCR was carried out in a rapid thermal cycler system (Roche Diagnostics 
GmbH) with duplicate reactions. The ﬂ uorescence was analyzed with LightCycler analysis 
software. The LighCycler run consisted of denaturation at 95°C for 420 seconds, ampliﬁ ed by 
performing 50 cycles of denaturation at 95°C for 15 seconds, annealing at 62°C for 5 seconds, 
and elongation at 72°C for 15 seconds. Melting curve analysis consisted of one cycle at 95°C 
for 0 seconds, 65°C for 15 seconds, and 98°C for 0 seconds in the step acquisition mode. The 
crossing point was deﬁ ned by the Second Derivative Maximum algorithm and arithmetic baseline 
adjustment. For relative quantiﬁ cation of expression levels we used the Relative Quantiﬁ cation 
Software version 1.0 (Roche Diagnostics GmbH), and the relative expression was calculated by 
calibrator-normalized relative quantiﬁ cation with efﬁ ciency correction. The gastric cancer cell-
line CRL-5822 was used as a calibrator as it overexpresses the DARPP32, TOP2A, and ERBB2 
genes. The relative standard curve with efﬁ cient correction (coefﬁ cient ﬁ le) was deﬁ ned for the 
target genes DARPP32, TOP2A, ERBB2, and B-actin, in triplicate reactions by using the calibrator 
in serial dilutions. 
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RESULTS
1. DNA COPY NUMBER CHANGES IN BARRETT ADENOCARCINOMA (STUDY I)
Aberrations were seen in 83% of tumors (15/18) with an average of 3.9 changes per patient 
(range 0 to 15). Gains were more frequent, with an average of 3.1 (range 0 to 11) per patient, than 
were losses, which averaged 0.88 (range 0 to 4) per patient. The most frequent gains were at 20q 
(56%), 17q (39%), and 7 (33%) (Fig. 4). High-level ampliﬁ cations were also observed in these three 
chromosomes. The most frequent losses were found in chromosomes 4 and 5 (22%).  
Figure 4.  Most frequently detected DNA copy number changes in Barrett adenocarcinoma patients. 
Gains are shown on the right side of the chromosomes, and losses on the left side. Thick bars 
represent high-level ampliﬁ cations.
2. DNA COPY NUMBER CHANGES AND ABERRATIONS OF CHROMOSOME 19 IN YOUNG 
GASTRIC CANCER PATIENTS (STUDY II)
2.1 Comparative genomic hybridization
DNA copy number changes were found in 17 of 22 (77%) tumors and in each of three cell lines. 
The most common gains in 14 intestinal-, two mixed- and six diffuse-type gastric cancer tumors 
and three gastric cancer cell lines were detected at 19q (68%), 20q (64%), and 17q (52%) (Fig. 5). 
The most frequent loss was observed in chromosome 4 (40%).  Alterations were more frequent 
in intestinal tumors (13 of 14 tumors (93%), average 6.6, range 0 to 11) than in diffuse tumors 
(average 0.6, range 0 to 4), of which only one was abnormal. DNA copy number changes were 
seen in both cases of mixed carcinoma. Frequent aberrations in intestinal-type gastric cancer were 
gains at 20q (86%), 19q (71%), and 17q (71%) and loss at 4q (50%). High-level ampliﬁ cations were 
seen at 17q, 18p, 19q, and 20.  
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Figure 5.  Aberrations most frequently observed in gastric cancer patients 45 years or younger and gastric 
cancer cell lines established from patients 45 years or younger. Gains are shown on the right 
sides of chromosomes and losses on the left. Solid lines represent the changes found in intestinal 
tumors; broken lines, mixed tumors; dotted lines, diffuse tumors; open bars, cell lines. High-
level ampliﬁ cations are shown with a thick bar.
2.2 Ampliﬁ cation at chromosome 19
CGH revealed gains and high-level ampliﬁ cations in the long arm of chromosome 19 in 68% 
of all the young cases and in 71% of the 14 tumors of intestinal subtype. The 19q region was 
characterized using interphase FISH and Southern blot. The BAC CTC-525D6 probe, mapped to 
the 19q12 region, revealed copy number increases in all eight tumor specimens studied (2.5-20 
average signals/nucleus). 
Six gastric cancer tumors, three gastric cancer cell lines and ﬁ ve normal controls were screened 
using a set of cDNA image clones (CCNE, CEBPA, AKT2, TGFB, and BCL3) mapped to 19q12-13.2, 
in Southern blot analysis (Table 6). CCNE was highly ampliﬁ ed in 3 of 9 (33%) cases.
Table 6.  Southern blot analysis of 19q in young gastric cancer patients.
Case
19q amplicon (CGH) 
10
Yes
11
Yes
12
Yes
15
Yes
23
SA
24
SA
25
Yes
26
Yes
27
Yes
Probe/location
CCNE/19q12 Yes No No No Yes No No Yes No
CEBPA/19q13 No No No No No No Yes Yes No
AKT2/19q13 No Yes No No No No No Yes No
TGFB/19q13 No No No No No No No No No
BCL3/19q13 No No No No No No No No Yes
Yes, ampliﬁ cation; no, no ampliﬁ cation detected
SA: Sample not available
CCNE, cyclin E; CEBPA, CCAAT/enhancer-binding protein ; AKT2, v-AKT murine thyoma viral oncogene 
homolog 2; TGFB, transforming growth factor ; BCL3, B-cell leukemia/lymphoma 3 
Two cases with the 19q amplicon (cases 10 and 14, intestinal type) and two cases with no 
chromosome 19 abnormalities (cases 17 and 19, diffuse type) were stained immunohistochemically 
for CCNE. CCNE protein overexpression was indicated in tumors with the 19q amplicon but not 
in tumors with no aberrations at 19q.
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3. ABERRATIONS AT CHROMOSOME 17 IN GASTRIC CANCER (STUDIES III, IV, V)
3.1 ERBB2 and GAS ampliﬁ cation in intestinal-type gastric cancer (Study III)
FISH analysis showed a concomitant ampliﬁ cation of the ERBB2 and GAS genes in all studied 
cases of intestinal-type gastric cancer tumors (7 cases) with the 17q amplicon, as previously 
revealed with CGH (Kokkola et al., 1997). For ERBB2 ampliﬁ cation the FISH signals ranged from 
2.5 to 20.5 per nucleus and for GAS ampliﬁ cation from 2.5 to 21.1 per nucleus. In three cases with 
high-level ampliﬁ cation detected by CGH, the signals ranged from 14.1 to 20.5 copies per nucleus 
for ERBB2 and from 16.1 to 21.1 copies per nucleus for GAS. The GAS gene ampliﬁ cation was 
detected only in gastric cancer, not in breast cancer. Eleven of 40 breast cancer cell lines had ERBB2 
ampliﬁ cation but none had GAS ampliﬁ cation.
Western immunoblotting was performed on the gastric cancer cell line CRL-5822, in which the 
17q gain was detected by CGH. The ERBB2 protein was upregulated to a high expression level 
and the GAS protein to a moderate level. 
3.2 Chromosome 17-speciﬁ c analysis using cDNA array (Study IV)
3.2.1 CGH array analysis
A total of 636 genes and ESTs of chromosome 17 were analyzed in a CGH array to determine the 
copy number levels of eight xenografts (X11, X27, X57, X71, X75, X79, X83, X95) and three cell 
lines (CRL-5822, CRL-5973, CRL-5974). All the xenografts and cell lines showed gain or high-level 
ampliﬁ cation at 17q by chromosomal CGH. The most ampliﬁ ed transcripts (ratio ≥ 1.5 in three 
or more of the cases studied) were of 11 known genes (ERBB2, TOP2A, GRB7, ACLY, PIP5K2B, 
MPRL45, MKP-L, LHX1, MLN51, MLN64, and RPL27) and of seven ESTs mapped to the 17q12-q21 
region. 
3.2.2 Expression analysis
cDNA-expression array analysis of eight xenografts (X43, X49, X57, X68, X75, X76, X80, X95) and 
the three cell lines (CRL-5822, CRL-5973, CRL-5974) using the chromosome 17-speciﬁ c cDNA 
array revealed ten transcripts with elevated expression (ratio ≥ 3.0 in three or more cases). Three 
of the transcripts [EST AA552509 (DARPP32), TOP2A, and ERBB2] also showed copy number 
increases in CGH array analysis. The most frequently overexpressed transcripts were EST 
AA552509 (DARPP32) (9/11, 82%) and TOP2A (9/11, 82%). ERBB2 was overexpressed in 27% 
(3/11) of cases. The other overexpressed genes and ESTs observed in the analysis were AOC3 
(5/11, 45%), JUP (4/11, 36%), ITAG3 (3/11, 27%), and KRT14 (3/11, 27%) mapped to 17q21, 
AP2B1 (4/11, 36%) mapped to 17q12, EST AA284262 (3/11, 27%) mapped to 17q23, and GRB2 
(3/11, 27%) mapped to 17q25. With the exception of xenografts X43 and X80, the other xenografts 
and cell lines analyzed had detectable ampliﬁ cations at 17q by chromosomal CGH. Expression 
analysis of DARPP32, TOP2A, and ERBB2 genes was validated by Northern blot with three cell 
lines (CRL-5822, CRL-5973, CRL-5974) included in the microarray study and one cell line without 
the 17q aberration (CRL-1739). Northern blot results were in agreement with the cDNA-array 
study; cell lines with protein overexpression (DARPP32 and/or TOP2A and/or ERBB2) showed 
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corresponding upregulation. DARPP32, TOP2A, and ERBB2 were not expressed in normal 
epithelial samples or cell line CRL-1739.
In addition to Northern blot, the expression analysis was veriﬁ ed with RT-PCR. Elevated 
expression of DARPP32 and TOP2A was observed in the xenografts and tumors. These genes 
were not expressed in pool of normal gastric epithelial tissues. 
3.3 DARPP32, TOP2A, and ERBB2 ampliﬁ cation and expression (Study V)
Ampliﬁ cation and expression levels of DARPP32, TOP2A and ERBB2 were examined in primary 
tumors of gastric cancer with a tissue array (78 cases, of which 52 were analyzable by ISH, 66 
analyzable by IHC) and quantitative real-time PCR (29 cases). In the tumor tissue array and 
quantitative real-time PCR study different patient series were used.
In situ hybridization of the tumor tissue array revealed concomitant ampliﬁ cation of DARPP32, 
TOP2A, and ERBB2 in 17% (9/52) of the tumor samples analyzed. Interestingly, analysis of 
the mRNA level (real-time PCR) revealed a different proﬁ le than the gene ampliﬁ cation. The 
most overexpressed gene was DARPP32 in 48% (14/29) of cases. TOP2A was overexpressed 
in 17% (5/29) and ERBB2 in 3% (1/29) of cases. Protein overexpression was validated by the 
immunohistochemical study, where overexpression of DARPP32 occurred in 45% (30/66) and 
of ERBB2 in 4.5% (3/66) of cases in the tumor tissue array. The tumor tissue array results are 
summarized in Table 7 and quantitative real-time expression results in Table 8.  Fourteen of the 
cases studied by IHC could not be analyzed by ISH. 
Table 7.  Summary of tumor tissue array results in ISH and IHC studies. Immunohistochemistry for 
TOP2A was not performed.
DARPP32
ISH
DARPP32
IHC*
ERBB2
ISH
ERBB2
IHC*
TOP2A
ISH
Total No. of studied cases 52/78 66/78 52/78 66/78 52/78
No. of positive cases 9/52 (17%) 30/66 (45%) 9/52 (17%) 3/66 (4.5%) 9/52 (17%)
No. of cases with 
concomitant ampliﬁ cation 
and overexpression 
4 3
* positive cases scored as 3+
Table 8.  Summary of results in quantitative real-time PCR study.
No. of positive cases DARPP32 TOP2A ERBB2
Intestinal 9/14 (64%) 2/14 (14%) 1/14 (7%)
Diffuse 5/14 (36%) 2/14 (14%) 0/14 (0%)
Mixed 0/1 (0%) 1/1 (100%) 0/0 (0%)
Total 14/29 (48%) 5/29 (17%) 1/29 (3%)
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DARPP32, TOP2A, and ERBB2 gene ampliﬁ cations were observed only in intestinal-type 
gastric cancer. Of the tumors included in the ISH study, forty were intestinal and twelve 
diffuse. At the mRNA level, overexpression of ERBB2 was detected only in the intestinal type, 
whereas TOP2A and DARPP32 were upregulated in both histological subtypes. TOP2A showed 
overexpression in 14% (2/14) of both the intestinal and diffuse tumors. DARPP32 overexpression 
was detected in 64% (9/14) of intestinal tumors and in 36% (5/14) of diffuse tumors.
At the protein level, overexpression frequency was in agreement with mRNA expression results. 
Four of the DARPP32 gene-ampliﬁ ed cases showed strong positive staining of the DARPP32 
protein. Another ﬁ ve such cases (DARPP32 ampliﬁ cation) were scored immunohistochemically 
as 1+ or 2+.  Accordingly, twenty-six tumors with strong DARPP32 protein expression had no 
gene ampliﬁ cation. Only three tumors showed strong ERBB2 protein expression. ERBB2 gene 
ampliﬁ cation was detected in each of the cases. Another six cases with ERBB2 gene ampliﬁ cation 
were scored as 0 or 2+ (two cases scored as 2+ and four cases scored as 0). 
Gene ampliﬁ cations were observed in tumor stages I to III. Elevated expression of DARPP32 
and TOP2A was detected in stages II to IV and ERBB2 overexpression (one case) in stage IV. As 
the number of the specimens was rather low, association between the stage and ampliﬁ cation/
expression could not be reliably concluded.
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DISCUSSION
1. DNA COPY NUMBER CHANGES AND TARGET CHROMOSOMAL REGIONS IN GASTRIC 
CARCINOMA AND BARRETT ADENOCARCINOMA
Our CGH results for the Barrett adenocarcinoma study suggest similarities in DNA copy number 
changes as previously revealed in intestinal-type gastric cancer (Kokkola et al., 1997; El-Rifai et 
al., 2001; Wu et al., 2001; Tay et al., 2003). These similarities are frequently ampliﬁ ed regions at 
chromosomes 17q and 20q, frequent gains at 7 and 8q, and losses in chromosomes 4 and 5. We 
also noted that DNA copy number aberrations are less frequent in diffuse-type gastric cancer. 
Comparative genomic analysis of copy number changes in young gastric cancer patients yielded 
averages of 8.3 and 0.7 changes in intestinal and diffuse tumors (Study II). These results are in 
concordance with those of other studies. Wu et al. (2001) reported the mean number of aberrations 
to be higher in intestinal-type gastric cancer (7.8 for intestinal/5.7 for diffuse). A study by Kokkola 
et al. (1997) produced similar results with the mean number of aberrations was 5.8 for intestinal 
tumors and 2.7 for diffuse tumors.
 Similarities in DNA copy number changes in intestinal-type of adenocarcinoma of the 
stomach and Barrett adenocarcinoma suggest common molecular pathogenetic features. These 
chromosomal regions are potential targets for discovery of novel candidate oncogenes and tumor 
suppressor genes associated with gastric tumorigenesis. Gain in the long arm of chromosome 17 is a 
recurrent alteration in intestinal-type gastric cancer and Barrett adenocarcinoma. Characterization 
of the target region for gene ampliﬁ cation has to take into account the methodological limitations 
of CGH. The minimum size of the ampliﬁ ed or deleted region that can be detected ranges from 5 
to 10 Mb (megabasepairs) [reviewed in (Forozan et al., 1997; Tachdjian et al., 2000)]. In case of high-
level ampliﬁ cation the sensitivity is higher. Chromosomal regions of 1 Mb are detectable when 
ampliﬁ ed 5-10 fold [reviewed in (Forozan et al., 1997; Tachdjian et al., 2000)]. 
Chromosomes 17 and 20 harbor several known genes and ESTs. Regions of chromosome 17, 
particularly 17q12-21 and 17q23, have been systematically studied in breast cancer (Barlund et 
al., 2000; Kauraniemi et al., 2001; Monni et al., 2001; Andersen et al., 2002). In addition to ERBB2, 
genes such as TOP2A and growth factor receptor-bound protein 7 (GRB7) are also observed 
ampliﬁ ed and/or overexpressed in breast cancer (Jarvinen et al., 1996, 1999; Depowski et al., 2000; 
Kauraniemi et al., 2001; Di Leo et al., 2002). Recently, alterations of ERBB2 and TOP2A have also 
been associated with bladder cancer (Simon et al., 2003). As discussed in section 4.2, in addition to 
gastric and breast cancer, the 17q gain is reported in other malignancies, such as neuroblastoma 
and Hodgkin lymphoma. Thus, these studies support the hypothesis that chromosome 17 
contains genes critical for tumorigenesis. Our aim was to characterize the target genes of 17q for 
ampliﬁ cation, and most importantly, for expression in gastric cancer using a cDNA array and 
other methods.
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2.  GENETIC ALTERATIONS IN YOUNG GASTRIC CANCER PATIENTS
To our knowledge, no CGH studies of younger gastric cancer patients have been published to 
date. The present study showed frequent DNA copy number changes in intestinal-type gastric 
cancer tumors. The majority of alterations were concentrated in the same chromosomal regions 
as observed in older gastric cancer patients, e.g., gains at 1q, 8q, 17q, and 20q and losses at 4 
(Kokkola et al., 1997; van Dekken et al., 2001; El-Rifai et al., 2001; Wu et al., 2001; Tay et al., 2003).
Despite the overall similarity in DNA copy number changes in young (≤ 45 years) and older 
gastric cancer patients, we observed ampliﬁ cation of chromosome 19 at a higher frequency in 
younger patients (68%) than in older patients (range 0 to 30%) (Kokkola et al., 1997; van Dekken 
et al., 2001; El-Rifai et al., 2001; Wu et al., 2001; Tay et al., 2003). Ampliﬁ cation in chromosome 19 
has been described in other human malignancies, e.g., myeloma, plasmacytoma, small cell lung 
cancer, adrenocortical tumors, and pancreatic tumors (Hoglund et al., 1998; Knuutila et al., 1998). 
The chromosomal region of 19q harbors several candidate oncogenes and genes previously 
associated with human malignancies that have been investigated by functional cell biology. 
Therefore we selected CCNE, CEBPA, AKT2, TGFB, and BCL3 for further investigation. Our report 
is the ﬁ rst to state that the 19q region contains genes that are dysregulated in young gastric cancer 
patients.
We identiﬁ ed one ampliﬁ ed and upregulated gene. Ampliﬁ cation and expression of cyclin E in 
young patients was demonstrated by Southern blot (three cases) and by immunohistochemistry 
in two cases with the 19q gain. Cyclin E forms a complex with cdk2 and regulates the transition 
from G1 to S phase in the cell cycle [see review (Donnellan et al., 1999)]. Cyclin-dependent kinase 
inhibitors p21 and p27 are involved in inhibition of cyclin E. p21 is transcriptionally regulated by 
p53 [(McWilliams et al., 1998) and references therein]. Ampliﬁ cation and upregulation of cyclin 
E has been found in other human neoplasms, e.g., ovarian cancer, breast cancer, and sarcomas 
(Donnellan et al., 1999; Farley et al., 2003; Schraml et al., 2003; Span et al., 2003), and in gastric cancer 
in older age groups (Akama et al., 1995; Sakaguchi et al., 1998; Lin et al., 2000b). Gene ampliﬁ cation 
and cyclin E upregulation are suggested to arise as an early event driving chromosomal instability 
in tumors overexpressing cyclin E (Spruck et al., 1999; Lin et al., 2000b). 
Other selected genes from the 19q region were less frequently ampliﬁ ed and TGFB was not 
ampliﬁ ed in any of the cases. LOH at TGFB is associated with several human malignancies, such 
as colorectal and pancreatic cancer [see reviews (Govinden et al., 2003; Kim et al., 2003)]. Mutation 
of the transcription factor CEBPA has been reported in acute myeloid leukemia (Pabst et al., 
2001). AKT2 is a serine/threonine protein kinase observed overexpressed in breast, ovarian, and 
pancreatic cancer (Okano et al., 2000; Sun et al., 2001; Tanno et al., 2001; Bacus et al., 2002; Arboleda 
et al., 2003). BCL3 translocation (14;19) is frequently detected in chronic lymphocytic leukemia 
(McKeithan et al., 1997). Overexpression of BCL3 is suggested to be involved in the development 
of anaplastic large cell lymphoma (Nishikori et al., 2003). 
Further comprehensive studies are needed to elucidate the biological and prognostic role 
of cyclin E in gastric cancer, particularly in young intestinal-type of gastric cancer patients. 
Because of its critical role in cell cycle regulation, cyclin E may be a target for studies of a possible 
prognostic factor or target gene in cancer therapy.
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3. TARGET GENES FOR AMPLIFICATION AND EXPRESSION AT 17q 
Studies by us and others indicate that DNA copy number increase at chromosomal region 17q 
is a frequent phenomenon in intestinal-type gastric cancer and Barrett adenocarcinoma. Table 1 
shows the frequencies of 17q gain found in various studies. The target genes within the ampliﬁ ed 
region were not deﬁ ned, however. In Study III, ERBB2 and GAS ampliﬁ cations were investigated 
in intestinal tumors, in which the ampliﬁ cation of 17q12-q21 was observed by CGH, and in one 
gastric cancer cell line, CRL-5822. The results showed concomitant ampliﬁ cation of the ERBB2 
and GAS genes. Analysis of cell line CRL-5822 by Western blot indicated strong expression of 
the ERBB2 protein and moderate expression of the GAS protein. The chromosomal region of 
17q harbors numerous genes and ESTs, however. In order to characterize the comprehensive 
ampliﬁ cation and expression proﬁ le of target genes for gastric cancer and Barrett adenocarcinoma, 
we used a custom-made chromosome 17-speciﬁ c cDNA-microarray. The GAS gene was not 
included in the cDNA-microarray chip and was investigated separately in Study III. 
Ampliﬁ cation and expression analysis of xenografts and cell lines revealed only three genes 
that were frequently ampliﬁ ed and overexpressed, DARPP32, TOP2A, and ERBB2. DARPP32, and 
TOP2A were the most overexpressed genes found in 9 of 11 cases (82%) (Study IV).
To reveal the ampliﬁ cation and expression status of DARPP32, TOP2A, and ERBB2 in primary 
gastric cancer tumors, we performed ISH and IHC on a tumor tissue array and quantitative real-
time PCR on primary tumor samples. ISH revealed gene ampliﬁ cations of DARPP32, TOP2A, and 
ERBB2 in 17% of cases, suggesting that 17q12-q21 is the minimum region of gain in intestinal-type 
gastric cancer. We were unable to show this ampliﬁ cation in diffuse-type gastric cancer (Study V), 
however, it should be taken into account that the number of analyzed intestinal tumors was higher 
than diffuse tumors. Interestingly, the mRNA expression levels of DARPP32, TOP2A, and ERBB2 
were not concomitant. DARPP32, TOP2A, and ERBB2 were overexpressed in 48%, 17%, and 3% of 
the tumor samples by quantitative real-time PCR. The mRNA expression level of tumor samples 
was compared to the gene expression level in normal epithelial samples. We performed IHC on 
the tumor tissue array to conﬁ rm that mRNA expression of DARPP32 and ERBB2 correlated with 
the protein level. It has to be taken into account that the ampliﬁ cation study (in situ hybridization) 
and expression study (real-time PCR) were performed on different patient series. On the other 
hand, we used the same tissue array in protein expression (IHC) and gene ampliﬁ cation (in situ) 
analyses of DARPP32 and ERBB2. The number of samples showing protein overexpression was 
in agreement with the results obtained from the real-time PCR study: 45% for DARPP32 and 4.5% 
for ERBB2. The threshold values for upregulation were critical in both studies; the threshold ratio 
was 1.0 for quantitative real-time PCR and scored as 3+ for the IHC studies.  
By real-time PCR, elevated ERBB2 expression was only seen in the intestinal tumors whereas 
increased expression of DARPP32 and TOP2A were frequently detected also in the diffuse tumors. 
The immunohistochemical ERBB2 experiment showed strong protein expression (scored as 3+) 
only for cases with gene ampliﬁ cation (three cases). This is a typical phenomenon also in breast 
cancer (Bilous et al., 2003). All three cases were of the intestinal subtype. Upregulation of DARPP32 
and TOP2A at the mRNA and/or protein levels were seen in both histological subtypes.
According to our results it is obvious that gene ampliﬁ cation is not the only mechanism 
for overexpression. In the tumor tissue array study, strong protein expression of DARPP32 
was detected in 30 cases, of which only four were found to have DARPP32 gene ampliﬁ cation. 
However, gene ampliﬁ cation is one important mechanism for overexpression. High-level copy 
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number ampliﬁ cation is recurrently associated with overexpression, as seen in ERBB2 in breast 
cancer (Kauraniemi et al., 2001; Hyman et al., 2002). In our study, all three cases with strong ERBB2 
protein expression were also found to have ERBB2 gene ampliﬁ cation. The CGH and cDNA 
microarray study of breast cancer by Hyman et al. (2002) revealed that 44% of highly ampliﬁ ed 
genes were indeed upregulated, supporting our ﬁ ndings. Recently, Vernimmen et al. (2003) 
studied the ERBB2 overexpression mechanism in breast cancer and other cancer cell lines. In 
breast cancer, overexpression of ERBB2 protein seemed to be associated with gene ampliﬁ cation 
and the transcription factor AP-2 level, whereas there was no correlation in non-breast cancer cell 
lines (ovary, prostate, liver, pancreas) 
3.1 DARPP32
Studies IV and V demonstrated DARPP32 as the most overexpressed gene in chromosome 17 
in gastric cancer. DARPP32 is a known gene associated with a neuronal signalling pathway. 
DARPP32, enriched in medium spiny neurons in the striatum, is a target for the dopamine-
induced signalling pathway (Ouimet et al., 1984, 1990; Walaas et al., 1984). DARPP32 protein 
contains four phosphorylation sites, at Thr34, Thr75, Ser102, and Ser137 (Greengard, 2001). DARPP32 
can function as either a kinase or phosphatase inhibitor, depending on which particular amino 
acid residue is phosphorylated (Hemmings et al., 1984; Bibb et al., 1999; Greengard et al., 1999). 
Phosphorylation of DARPP32 at the Thr34 site by protein kinase A (PKA) inhibits the activity of 
protein phosphatase 1 (PP-1) (Greengard et al., 1999; Hemmings et al., 1984). Phosphorylation at 
the Thr75 site by cyclin-dependent kinase 5 (CDK5) converts DARPP32 into an inhibitor of PKA 
(Bibb et al., 1999). A recent ﬁ nding is a novel truncated isoform of DARPP32, termed t-DARPP, 
that lacks the Thr34 phosphorylation site and is therefore not a PP-1 inhibitor (El-Rifai et al., 2002). 
Both isoforms were overexpressed in gastric cancer (El-Rifai et al., 2002). The primers we used in 
Study V recognized both isoforms. 
Dephosphorylation and phosphorylation of proteins are important in the regulation of 
different cell cycle functions [reviewed in (Berndt, 1999; Sridhar et al., 2000)]. PP-1 associated 
with cell growth control in several functions, e.g., exit from mitosis, blocking of the cell cycle 
and activation of apoptosis (Berndt, 1999; Wang et al., 2001). Wang et al. (2001) demonstrated 
that dephosphorylation of target proteins by PP-1 may be critical for the initiation of apoptosis. 
One of these target proteins is retinoblastoma protein (pRB) (Wang et al., 2001; Yan et al., 1999). 
Dephosphorylation of pRB by PP-1 is followed by caspase-activated phospho-pRB cleavage, 
which ﬁ nally leads to apoptosis. Inhibition of PP-1 activity by the phosphorylated form (by pKA 
at Thr34) of DARPP32 increases the phosphorylation level of various other proteins (Hemmings 
et al., 1984). An increase in the phosphorylation level will affect cell cycle regulation through 
phoshorylation of pRB and subsequent inhibition of apoptosis.
DARPP32 is also associated with phosphorylation regulation in the MAPK and cyclic AMP 
response element (CRE)-binding protein (CREB) signalling pathways (Shaywitz et al., 1999; Yan 
et al., 1999). CREB is a transcription factor involved in many cellular functions. Studies of striatal 
neurons have indicated that phosphorylation of CREB is prolonged in DARPP32 expressing cells 
[(Shaywitz et al., 1999) and references therein]. 
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3.2 TOP2A  
Frequent ampliﬁ cation and overexpression of TOP2A was demonstrated in gastric cancer cell lines, 
xenografts, and primary tumors (Studies IV and V). TOP2A belongs to the DNA topoisomerase 
family, whose members have important functions breaking and rejoining DNA during normal cell 
growth. TOP2A catalyzes transient double-stranded breaks and passage of double-stranded DNA 
in ATP-dependent reactions during DNA replication, chromosome condensation and segregation 
[see review (Watt et al., 1994)]. In primary tumors (Study V), ampliﬁ cation of the TOP2A gene was 
observed in 17% of cases and overexpression in 17% of cases. Gene ampliﬁ cation was found only 
in intestinal-type tumors, which is in agreement with our previous CGH results. Overexpression 
of TOP2A was also detected in diffuse-type tumors (14% intestinal, 14% diffuse). This was the 
ﬁ rst study to systematically characterize ampliﬁ cation and expression levels of TOP2A in primary 
gastric cancer tumors. It must be taken into account that the number of studied tumors was rather 
small and the ampliﬁ cation and expression studies were performed for different series of patients 
(Study V). These studies suggest, however, that TOP2A ampliﬁ cation indicates overexpression 
of TOP2A protein in intestinal gastric cancer. Overexpression of TOP2A has important clinical 
signiﬁ cance. TOP2A is a molecular target for several anticancer drugs (e.g., etoposide and 
doxorubicin) (Harris et al., 2001), [reviewed in (Hande, 1998; Beck et al., 2001; Li et al., 2001)].
  
3.3 ERBB2
  
ERBB2 is a frequently ampliﬁ ed and overexpressed oncogene in breast cancer and considered as 
a prognostic factor [(Toikkanen et al., 1992; Jarvinen et al., 1996; Ross et al., 1999; Depowski et al., 
2000; Tanner et al., 2001; Di Leo et al., 2002; Menard et al., 2003) and references therein]. ERBB2 
gene ampliﬁ cation and/or overexpression occurs in approximately 15 to 30% of breast cancer 
cases [(Ross et al., 1999; Tanner et al., 2001; Nabholtz et al., 2002; Menard et al., 2003) and references 
therein]. In breast cancer, ampliﬁ cation of ERBB2 is used as a biomarker for patients who respond 
to anti-ERBB2 (Herceptin) therapy. ERBB2 is part of the ERBB (HER) tyrosine kinase receptor 
family that has an essential role in various signalling cascades in normal cell development [see 
reviews (Baselga et al., 2002; Holbro et al., 2003)]. Alterations of ERBB receptors, particularly of 
ERBB2 and EGFR, are linked to tumorigenesis.
Our results indicated ERBB2 ampliﬁ cation in 17% of the intestinal cases, which is in agreement 
with previous gastric cancer studies. The frequency of tumors with ERBB2 overexpression was, 
however, lower than the frequency of tumors with ERBB2 gene ampliﬁ cation, 3% by real-time 
PCR and 4.5% by IHC. The upregulation value was correlated with the deﬁ ned threshold value. 
In our studies, the threshold values for quantitative real-time PCR and IHC were critical. In the 
IHC study we accepted as a positive result only cases that were scored as 3+. If we consider 
also cases scored 2+ as positive, the frequency of protein overexpression rises to 11%, which is 
closer to the frequency of ampliﬁ cation. Five of the nine ERBB2 gene-ampliﬁ ed cases showed 
immunohistochemical staining scored as 2+ or 3+. Some gastric cancer studies of ERBB2 have 
applied 2+ as the threshold value in IHC (Takehana et al., 2002). 
Our results suggest that the ERBB2 gene is coampliﬁ ed in the ampliﬁ ed 17q12-q21 region, but 
not as frequently upregulated according to the critical threshold values. According to previous 
studies, overexpression frequency of ERBB2 appears to be lower than gene ampliﬁ cation 
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frequency in gastric cancer (see section 4.3.1) [(Lin et al., 2000a) and references therein], (Ooi et al., 
1998; Takehana et al., 2002).
3.4 GAS
Gastrin is a peptide hormone secreted by G cells in the gastric antrum. It stimulates gastric acid 
secretion and functions also as a growth factor for parietal, enterochromafﬁ n, and mucous cells 
of the gastric epithelium [see review (Todisco et al., 1997)]. Gastrin is a potential growth factor 
for gastric tumors [(Todisco et al., 1997; Stepan et al., 1999) and references therein]. It induces the 
MAPK and RAS pathways through cellular receptors CCKA and CCKB in enterochromafﬁ n-like 
(ECL) cells, stimulating the mitogenic signal for cellular growth (Todisco et al., 1997; Stepan et al., 
1999). The major molecular form of gastrin produced in the antrum is G17, but glycine extended 
gastrin (G-Gly) has also been detected. In Study III we demonstrated GAS gene ampliﬁ cation 
in gastric cancer cases and a cell line, and overexpression of gastrin in a gastric cancer cell line. 
The overexpression of gastrin in gastric carcinoma has been demonstrated in several reports, but 
GAS gene ampliﬁ cation has not been studied previously (Rakic et al., 1991; Okada et al., 1996; 
McWilliams et al., 1998; Konturek et al., 2000; Henwood et al., 2001). Recent studies with transgenic 
mice models have implicated an important role for overexpressed gastrin in tumorigenesis (Wang 
et al., 1996, 1999). 
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SUMMARY AND CONCLUSIONS
The aim of this thesis was to investigate the cytogenetic and molecular genetic changes in gastric 
carcinoma and Barrett adenocarcinoma, and to expand the characterization of a certain frequently 
ampliﬁ ed chromosomal region. 
 The chromosomal region of 17q is frequently ampliﬁ ed in intestinal-type gastric cancer. The 
17q gain was detected as a recurrent aberration also in Barrett adenocarcinoma (Study I). DNA 
copy number changes, including the frequently ampliﬁ ed region of 17q, showed overall similarity 
in young (≤ 45 yrs) and older gastric cancer patients. We found however, that the chromosomal 
region of 19q was more frequently ampliﬁ ed in young gastric cancer patients than in older 
patients (Study II). 
The chromosome 17q region was fully characterized by cDNA-array. Three genes, DARPP32, 
TOP2A, and ERBB2, were most frequently found ampliﬁ ed and overexpresssed (Study IV). 
Ampliﬁ cation and expression of these genes were investigated in primary gastric carcinoma 
tumors. Concomitant ampliﬁ cations of DARPP32, TOP2A and ERBB2 were found only in the 
intestinal subtype (17%). Interestingly, DARPP32, TOP2A, and ERBB2 were not concomitantly 
upregulated. DARPP32 was the most upregulated gene in primary gastric cancer tumors 
by quantitative real-time PCR (48%), suggesting another mechanism, in addition to gene 
ampliﬁ cation, for DARPP32 protein overexpression (Study V). Frequency of TOP2A and ERBB2 
upregulation was lower (17% and 3%, respectively). The GAS gene, mapped to 17q21, was also 
found to be frequently ampliﬁ ed (Study III). These genes are known to be involved in critical 
pathways, such as MAPK and CREB cascades, that are important for tumorigenesis. 
The 19q region harbors several candidate oncogenes that play important roles in tumorigenesis, 
for example through cyclin dependent kinase regulation and the AKT signalling pathway. We 
conﬁ rmed the ampliﬁ cation and overexpression of one candidate gene, cyclin E, in young gastric 
cancer patients (Study II).
This study has revealed information concerning aberrations in several chromosomal regions, 
and narrowed down the critical candidate genes that could be the focus of further studies. Gene 
ampliﬁ cation is one of the important mechanisms for gene overexpresssion. It is even more 
important to characterize the overexpressed genes and the target proteins that are responsible for 
biological functions in cell. Functional studies of protein levels and signalling pathways can be 
expected to provide more information concerning the mechanism that leads to cancer, and will 
thus aid in the design of more efﬁ cient and speciﬁ c cancer treatments. 
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